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Cardiovascular disease (CVD), defined by the World Health Organization (WHO) as
diseases that involve the heart and/or blood vessels is the number one cause of morbidity
and mortality worldwide. In the United States more health care dollars are spent managing
and treating CVD and/or its complications than any other disease process. Coronary heart
disease (CHD) is the leading cause of deaths (43.8%) attributable to CVD, followed by stroke
(16.8%), hypertension (9.4%) and heart failure (HF) (9%). CVD-related deaths and attendant
morbidities, which include lifelong disability are in many cases preventable.
This research proposes a dynamic risk model that handles multi-type recurrent events
with a dependent terminating event in a competing risk framework, specifically nonfatal MI,
stroke and HF, with all-cause mortality (death) as the dependent terminating event. A unique
feature of this model is that it directly quantifies the baseline hazard for each recurrent CVD
event and death, and the additional hazard that each recurrent event confers to its own
recurrence and all other events. Positive and negative associations and relationships between
all event types, recurrent and terminating, are established. The baseline hazard is dynamically
updated with each event occurrence and affected by the types and number of events up to

that point. The model is validated with a simulation study and applied to the Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study. A procedure to
assess the goodness of fit of the model is detailed.
The model is further extended to incorporate risk factors for MI, stroke, HF and death
such that each event type has unique risk factors [intrinsic hazards covariate model 1 (IHCM
1)]. Risk factors for the 4 event types imparted by antecedent nonfatal events is also
established [intrinsic and recurrent hazards covariate model (IRHCM)]. Heterogeneity of
ALLHAT treatment arm effects (amlodipine vs chlorthalidone; lisinopril vs chlorthalidone) on
hazards by subgroup [sex, diabetes, race (black/nonblack), age, kidney disease, atrial
fibrillation, hypertension treated at baseline, and stage 1/stage 2 hypertension] is studied
(IHCM 2).
Stabilization, fine tuning and validation of the model is performed by supervised
learning, utilizing bagged training sets (70% and 60%) and test sets (30% and 40%) of IHCM 1
(250 bagged sets) and IRHCM (200 bagged sets, 70/30 training/test sets). Parameters are
tuned and 95% confidence intervals (CI’s) constructed by the mean and standard deviation of
the estimated parameters of the bagged training sets, respectively. Training set parameters
applied to corresponding test sets yield similar and consistent goodness of fit measures for
IHCM 1 and IRHCM, which suggests good generalization of the model without overfitting.
Given the enormous global burden of CVD, this model is of great clinical import with
significant potential to prevent and reduce future CVD events and develop into a risk
assessment tool/decision rule, particularly in high-risk patients and delineate optimal
treatment strategies tailored to the individual’s clinical profile.
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE
Cardiovascular disease
Cardiovascular disease (CVD), defined by the World Health Organization (WHO) as
diseases that involve the heart and/or blood vessels is the number one cause of morbidity and
mortality worldwide.1 According to WHO statistics, of the 57 million global deaths in 2008, 17.3
million (30%) were due to CVD, of which 7.3 million were attributed to myocardial infarctions
(MI) and 6.2 million were due to strokes.1 The impact of CVD on human health, quality of life and
longevity cannot be overstated. In the United States alone, more health care dollars are spent
managing and treating CVD and/or its complications than any other disease process.2 In 2015,
2.7 million resident deaths were registered in the United States, and 10 leading causes of death,
of which heart disease was number one and stroke was 5th, accounted for 74.2% of those deaths.2
Coronary heart disease (CHD) is the leading cause of deaths (43.8%) attributable to CVD, followed
by stroke (16.8%), hypertension (9.4%) and heart failure (HF) (9%). Deaths and attendant
morbidities that arise from CVD are in many cases preventable.1,2
According to the latest figures from the American Heart Association (AHA)2, by 2035 over
135 million adults in the United States (45.1%) are projected to have CVD of some type, and total
costs of CVD are expected to reach $1.1 trillion, with direct medical costs projected to reach
$748.7 billion and indirect costs $368 billion.
Subtypes, pathophysiology and risk factors
There are two main types of CVD. The first type is due to atherosclerosis1 and includes
coronary artery disease (CAD)/ischemic heart disease, cerebrovascular disease such as stroke,
and diseases of the aorta and arteries, which include hypertension and peripheral vascular
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disease. The second type of CVD includes congenital heart disease, rheumatic heart disease,
cardiomyopathies and cardiac arrhythmias.1-3 Atherosclerotic CVD is much more common and
furthermore, deaths due to myocardial infarction (MI) and stroke comprise the vast majority of
CVD deaths.1-3 The vast majority of strokes are ischemic (87%), and the remainder hemorrhagic,
which is secondary to rupture of a blood vessel that is usually secondary to hypertension.2
Atherosclerosis is the underlying disease process that results in MI and the vast majority
of strokes. The pathophysiology of atherosclerosis is complex, and a brief summary will be
presented here. Atherosclerosis is an inflammatory process that affects medium and large
vessels.1,3 The endothelium of these vessels, when exposed to elevated levels of low-density
lipoprotein (LDL) particles and other substances such as free radicals, becomes permeable to
lymphocytes and monocytes. These cells migrate into the intimal layer (second layer, just below
the endothelium) of the blood vessel. LDL particles are further attracted to this site due to a series
of reactions, and are engulfed by the monocytes, which then transform into macrophages (foam
cells). Smooth muscle cells migrate to the site from the tunica media (the deeper layer of the
vessel, below the intimal layer). A fibrous cap eventually forms, consisting of smooth muscle and
collagen. The foam cells begin to die, which forms a necrotic core that is covered by the fibrous
cap. These lesions are known as atheromatous plaques, and they enlarge as cells and lipids
continue to accumulate in them. The plaque begins to bulge into the vessel lumen, and as the
process continues, the fibrous cap thins out, accompanied by fissuring of the endothelial surface
of the plaque. This plaque may rupture, and when it does, lipid fragments and cellular debris are
released into the vessel lumen. These fragments and debris are exposed to thrombogenic agents
on the endothelial surface, which starts a cascade that results in a thrombus, or blood clot. If the
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thrombus is large enough, and it results in blockage of a coronary artery or cerebral artery, it
causes an MI or stroke, respectively.1,3
HF occurs when an abnormality of cardiac function results in failure to provide adequate
blood flow, or perfusion to meet the body’s metabolic needs, specifically of tissues and organs.
HF also occurs when there is an excessive rise in cardiac filling pressures.3 In the United States,
the leading cause of heart failure (HF) is ischemic heart disease.3 The AHA2 reports that according
to NHANES data from 2011 to 2014, an estimated 6.5 million Americans aged 20 and above had
HF, which is an increase from the 5.7 million reported from 2009 to 2012. AHA projects that the
prevalence of HF will increase 46% from 2012 to 2030. In 2012, total cost for HF was an estimated
$30.7 billion of which 68% was attributed to direct medical costs. Recurrent hospitalizations after
HF diagnosis is a significant source of health care expenditures; additionally, physician office visits
and ED visits for HF also contribute to costs.2
Key ALLHAT CVD findings
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT) was a landmark clinical trial that sought to determine whether incidence of fatal CHD
or nonfatal MI was lower for high-risk hypertensive patients treated with a calcium channel
blocker (CCB) or an angiotensin converting enzyme (ACE) inhibitor as compared to treatment
with chlorthalidone, a thiazide diuretic.4-6 Diuretic are less expensive than CCB’s and ACE
inhibitors; the treatment and complications of hypertension are a significant source of health
care costs.2 Appropriate treatment of hypertension is imperative given its significant role in CVD,
both as a subtype of CVD and as a precipitator of other CVD processes. ALLHAT results showed
that incidence of fatal CHD and nonfatal MI combined did not differ between the treatment
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groups, and similarly, all-cause mortality also did not differ between the treatment groups. HF
was a secondary outcome in ALLHAT; both amlodipine and lisinopril had a higher 6-year rate of
HF than chlorthalidone. Lisinopril had a higher 6-year rate of stroke compared to chlorthalidone
as well. Chlorthalidone also performed well in controlling hypertension; it outperformed both
amlodipine and lisinopril in controlling systolic blood pressure (SBP) at the 5-year mark.4 A later
paper by Cushman et al.6 examined post-trial ALLHAT results 8-13 years post-randomization and
found similar results for the primary endpoint of combined fatal CHD and nonfatal MI; there were
no significant differences between the 3 treatment arms. For secondary outcomes, amlodipine
had higher HF hazard and lisinopril had higher stroke hazard compared to chlorthalidone.6
These important findings from ALLHAT underscore the importance of both the initial
incidence of CVD, e.g. MI, stroke or HF, and later incidence of these disease processes in that
individual. All three disease processes are recurrent; each individual who does not die from the
first manifestation of the disease has the likelihood – usually an increased likelihood according
to the natural history of the disease – of having it recur. A thorough study of MI, stroke and HF
recurrent events in the full cohort of ALLHAT participants randomized to the 3 treatment arms
(𝑛 = 33,357) has never been conducted. Such a study would yield valuable insight into the
optimal treatment and important risk factors for high-risk hypertensive individuals - not only to
prevent the first occurrence of disease, but also to prevent further recurrences and ultimately,
death.
Multi-type recurrent events
The statistical methodology and analysis of recurrent events in survival and longitudinal
data in various clinical settings has been explored in the literature. In recurrent events data, an
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event of interest can occur more than once in the same individual under observation. Multi-type
recurrent events refer to the situation in which more than one particular event type can occur in
the same individual, and that event type can occur more than once. These multiple types of
recurrent events may or may not be associated, or correlated with one another.7 Additionally,
multi-type recurrent events may have an accompanying terminal event, such as death, after
which no further events can occur. This terminal event may or may not be related to the recurrent
events.7
Cook and Lawless7 included a chapter on various approaches for multi-type recurrent
events, including intensity-based models, random effects models, rate and mean functions, and
multistate models. These models can be extended to the multivariate case to include covariates
associated with the events themselves, and which may explain relationships between the
different event types. Furthermore, these models can also be extended to handle a dependent
or independent terminal event. Intensity-based models are flexible; they can be modified to
capture possible associations between multiple event types if event types are related, and to
potentially handle multiple event types in conjunction with a co-occurring dependent
termination process such as death. However, the authors suggest that parsimonious models are
preferred in this context so the number of covariates may be limited and characterizing the
associations between event types can be challenging. Random effects models are also flexible,
but may require some specification of the variance-covariance matrix of the component random
effects to describe associations between different event types, and may prove challenging to
estimate depending on the likelihood function and optimization method.7 Multistate models are
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not ideal for multi-type recurrent events as too many states are likely to appear which
significantly increases computational burden.7
Numerous authors have proposed and utilized recurrent events models in various clinical
settings for single-type and multi-type recurrent events with and without (possibly dependent)
termination. Clegg, Cai and Sen8 proposed a multivariate marginal mixed baseline hazards model
and applied the model to analyze two types of recurrent events: coronary heart disease (CHD)
and cerebrovascular accident (CVA) in individuals from the Framingham Heart Study. The
sampling unit was a cluster, i.e. family unit (for example, a married couple with children). The
study utilized different baseline hazards for recurrent events CHD and CVA, and identical baseline
hazard for siblings. A strength of the study was the ability to avoid imposing specific dependence
structures on the different recurrent event types that are usually required in most frailty models.
However, an important drawback of this model and study is that it did not account for death as
a dependent termination event 8; both CHD and CVA are known to increase mortality.1-3
Mazroui et al.9 utilized a multivariate frailty model for two types of recurrent events and
their association with each other, and with a dependent terminal event in the setting of breast
cancer. They proposed two estimation models for their model: likelihood maximization for
models with a parametric piecewise constant baseline hazard function and maximization of the
penalized likelihood for models with baseline hazard functions approximated by M-splines. The
two recurrent event types were locoregional and metastatic relapse after breast cancer
diagnosis. A major strength of their model is that the two recurrent event processes may not be
independent or conditional on frailties and covariates; thus, the related processes of the two
types of recurrent relapse after breast cancer diagnosis are accounted for, along with death as
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the dependent, terminating event. Details of their parameter estimation procedures and model
diagnostics/validation can be found in the paper.9
Zhu et al.10 proposed a joint modeling approach of semiparametric transformation
models that was an extension of previous models for univariate recurrent and terminal events,
to handle multivariate, multi-type recurrent events in the setting of a dependent terminal event.
The EM algorithm was utilized for maximum likelihood estimation of parameters. They applied
their model in the setting of childhood cancer survival, with the two recurrent event types being
(1) recurrence of the original cancer and (2) occurrence of new cancers, and death being the
dependent terminal event. Cai and Shaubel11 developed a class of semi-parametric marginal
means/rates regression models for multi-type recurrent events (hospitalizations and physician
office visits) in the setting of childhood asthma outcomes; however, their model does not account
for a potentially dependent terminal event, nor provide inferences on the possible correlation
structures between event types.
Chen and Cook12 utilized cumulative mean functions for multi-type recurrent events with
dependent termination (death) by conducting separate marginal analyses, with each analysis
focusing on one recurrent event type. They applied their methods to patients with breast cancer
metastasis to bone experiencing multiple types of skeletal complications, and the effect of
bisphosphonate therapy on such recurrences. A subsequent paper by Chen et al. 13 developed
methods based on marginal models for multi-type interval-censored recurrent events, i.e. when
the precise event times are unobserved, but the event is known to have occurred within a certain
time interval. They utilized the Gibbs sampling algorithm to aid in model fitting and inference.
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For single-type recurrent events approaches in multiple clinical scenarios, we refer to
Chang, Chan and Kapadia 14; Lin, Wei, Yang, et al.15 Ghosh and Lin 16; Liu, Wolfe and Huang 17; Yu
and Liu 18; Belot, Rondeau, Remontet, et al.19 and Maugen, Rachet, Mathoulin-Pelissier, et al.20
Recurrent events in CVD
There are very few studies that examine the multi-type recurrent events process with
death as the dependent terminal event in the important clinical setting of cardiovascular disease.
A recent paper by Lin, Luo, Chen, et al.21 proposed a model that handles multi-type recurrent
events with dependent termination in the setting of cardiovascular disease on a smaller subset
of the ALLHAT clinical trial (ALLHAT-LLT). Theirs is a multivariate joint frailty model with
nonparametric covariate functions in a Bayesian inference framework. They used the cubic-Bspline basis for their nonparametric covariate functions, and Bayesian inference based on Markov
Chain Monte Carlo (MCMC) to estimate the parameters. They compared the performance of
three models in simulation studies: the joint model, the reduced model (the recurrent and
terminal events were modeled independently) and the parametric model (the nonparametric
covariate functions were modeled as linear functions). For their datasets, they generated two
types of recurrent events and a terminal event in two different simulation settings. For simulation
setting I there was no correlation between multi-type recurrent events and the terminal event.
For setting II there was a positive correlation between recurrent events and the terminal event
such that the subjects with higher risks of recurrent events were at higher risk of the terminal
event. The joint model performed well in both simulation settings; in the first setting of
independent termination (consistent with the reduced model), the joint model performed
comparably to the reduced model, and in the second setting of dependent termination, the joint
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model markedly outperformed the reduced model. The joint and reduced models outperformed
the parametric models in both simulation settings. When they applied all three models to the
ALLHAT-LLT data, the models’ performances were similar to that of the simulations. Their key
findings included significant positive correlation between risk of CHD and stroke, and risk of CHD
and heart failure conditional on the observed risk factors. This suggests that subjects with one
type of CVD event are very likely to experience another type of CVD as compared to those
without. They also found that risks of recurrent CHD were positively associated with death/allcause mortality conditional on the observed risk factors, although stroke and HF did not show
significant correlation with death. For further details on their statistical models, simulation
studies and ALLHAT-LLT results, we refer to Lin, Luo, Chen, et al.21
We wanted to develop a new statistical model for multi-type recurrent events with a
dependent terminal event that can characterize the possible relationships between the different
event types and the relationship of each event type with the terminal event. Furthermore, we
wanted our model to be easily extended to the multivariate case such that covariates can be
included. We aim for our model to be straightforward in its derivation and implementation, and
flexible and adaptable to a variety of clinical settings. Our proposed statistical model is motivated
by the ALLHAT clinical trial, specifically the in-trial cohort randomized to the treatment arms
chlorthalidone, amlodipine and lisinopril.4,5
Public health and clinical significance
CVD is one of the most important clinical and public health problems of our time, bar
none. Prevention of CVD by identifying important risk factors and optimal treatment strategies
once CVD has developed in an individual would go a long way towards reducing the burden of
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disease and mortality, both globally and right here in the United States. Health care costs of CVD
would be reduced in a significant way. A key component of CVD prevention and effective
management is to not only reduce the incidence of first disease, but also recurrent disease
processes that are related to the first. MI and stroke are acute, often severe and life-threatening
manifestations of CVD that have an underlying, shared component of atherosclerosis, upon
which plaque rupture and the subsequent cascade of events that leads to thrombus formation in
the artery is the precipitating event.1,3 HF is known to have MI and coronary heart disease (CHD)
as one of its main causes 3 and is a chronic disease process with acute exacerbations that may be
severe and life-threatening. We believe that studying these three particular related disease
processes that are recurring and comprise such a huge portion of CVD burden in the statistical
framework of multi-type recurrent events with dependent termination, in this case death i.e. allcause mortality, is urgently needed.
Aims and objectives
Aim 1: To derive and develop a statistical model to describe dynamic risk of multi-type recurrent
events in a competing risk framework.
Aim 2: Apply the model specifically to examine the competing risks of three types of recurrent
CVD events: MI, stroke, and heart failure (HF) in the ALLHAT dataset and the dependent
terminating event, death.
Aim 3: Utilize the model to identify and quantify important clinical risk factors and treatment
options for each of the three multi-type recurrent events, and death.
Aim 4: Develop a supervised learning approach for parameter tuning with variable selection,
model stabilization and model validation.
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CHAPTER 2: JOURNAL ARTICLE 1
A dynamic competing risk model for multi-type recurrent events with dependent termination
Abstract
Multi-type recurrent events are a common feature of longitudinal studies. In many cases, there
is a terminating event such as death, after which no further events can occur. The terminating
event may or may not be associated with the recurrent events. We propose a dynamic risk model
that handles multi-type recurrent events with a dependent terminating event in a competing risk
framework. A unique feature of our model is that it directly provides the baseline hazard for each
type of recurrent event and the terminating event, and the additional hazard that each recurrent
event confers to all other events. In this manner, positive and negative associations and
relationships between all event types, recurrent and terminating, are established. The baseline
hazard is dynamically updated with each event occurrence, and is affected by event history (the
number and types of past events) and covariates. We validate our model with a simulation study.
The model is applied to the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial (ALLHAT) study and the findings described. Furthermore, a procedure developed to
assess goodness of fit of the model is detailed. We provide a discussion of the results and their
clinical implications.
Keywords: baseline hazard; competing risk; multi-type recurrent events; dependent termination;
cardiovascular disease

11

1. Introduction
Recurrent events, where one or more types of events can occur repeatedly in the same individual
are a common feature of longitudinal studies. Examples of single-type recurrent events include
cancer relapses, chronic obstructive pulmonary disease (COPD) exacerbations, recurring
opportunistic infections and recurrent heart failure (HF) episodes. Multi-type recurrent events
refer to the situation in which more than one particular event type can occur in the same
individual, and that event type can occur more than once. Such multiple types of recurrent events
may or may not be associated or correlated with one another. In both single-type and multi-type
recurrent events, death from any cause will be a terminating event after which no further events
can occur. The terminating event may be associated with preceding events; for example, it is
known that nonfatal myocardial infarction (MI), nonfatal stroke and nonfatal HF individually
increase the risk of subsequent death.1
Recurrent events models are widely reported in the literature. For single-type recurrent
events models in various clinical scenarios, we highlight the works of Lin et al.,2 Chang et al.,3
Ghosh and Lin,4 Liu et al.,5 Yu and Liu,6 Belot et al.7 and Maugen et al.8 For multi-type recurrent
events, Cook and Lawless9 included a chapter on various approaches, including intensity-based
models, random effects models, rate and mean functions, and multistate models. An important
aspect of multi-type recurrent events models in particular is their ability to characterize potential
associations between recurrent events; an event can increase the risk of a subsequent event of
the same type, or of a different type, or both. Furthermore, such a model should also characterize
the association between each type of recurrent event and a dependent terminal event if it exists.
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In clinical contexts, the dependent terminal event is usually death. We briefly mention several
models that meet these demands here.
Zhu et al.10 proposed a joint modeling approach of semiparametric transformation
models that was an extension of previous models for univariate recurrent and terminal events,
in the setting of childhood cancer survival with the two recurrent event types being recurrence
of the original cancer and occurrence of new cancers, and death being the dependent terminal
event. Mazroui et al.11 utilized a multivariate frailty model for two types of recurrent events and
their association with each other, with death as the dependent terminal event in the setting of
breast cancer. Lin et al.12 proposed a multivariate joint frailty model with nonparametric
covariate functions in a Bayesian inference framework that handles coronary heart disease
(CHD), stroke and HF as multi-type recurrent events with death as the dependent terminating
event.
The baseline hazards of events, including recurrent events are often of significant interest
in longitudinal studies. The semi-parametric Cox proportional hazards model reduces to the
product limit estimate in the case of no covariates, which provides an estimate of the baseline
hazard function as a straightforward transformation of the survival function. 13 Breslow14
provided a similar estimate. However, these approaches do not address baseline hazard
functions for recurrent events. Furthermore, parametric baseline hazard functions for recurrent
events may be desired in certain situations. To our knowledge, there has not been to date a multitype recurrent events model that can accomplish the following: 1) directly quantify the specific
baseline hazard, or absolute risk, that each nonfatal event confers on itself to recur, every other
nonfatal event of interest to occur or recur in future, and death (the terminating event) to occur;
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2) update the baseline hazard of every nonfatal event and death with the occurrence of each
nonfatal event; 3) express the dynamic risk of each nonfatal event and death as an accumulation
of separate, unique baseline hazards that arise from the event history, which yields new
information and insights into the clinical problem being studied. In this paper, we show that our
model, motivated by the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
Trial (ALLHAT) study meets these objectives and several additional ones. Throughout this paper,
we will use the terms hazard and risk interchangeably.
The remainder of this paper is organized as follows. In Section 2, we introduce our multitype recurrent events model with a dependent terminal event. Statistical inference of the model
parameters and numerical approaches are described in Section 3. In Section 4, we present a
simulation study that validates our estimation methods. Section 5 details the application of our
model to the landmark ALLHAT clinical trial. We provide discussion of our results and state our
conclusions in Section 6.

2. Model
2.1 Model Formulation
Let 𝑇𝑀 , 𝑇𝑆 , 𝑇𝐻 and 𝑇𝐷 be the times at which the next MI, stroke, HF episode (henceforth referred
to as HF and all of these events will be assumed to be nonfatal) and death from any cause
(henceforth death) occur, respectively; specifically: 𝑇𝑀 , 𝑇𝑆 , 𝑇𝐻 and 𝑇𝐷 represent the times elapsed
from the time point of interest. We assume that (1) two or more events cannot occur
simultaneously, i.e. in an infinitesimally small time interval ∆𝑡 only one event can occur; (2) the
probability of occurrence of any type of event in the future depends on the cumulative number
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and types of events up to the current time. From (1), for any event type 𝑤 (where 𝑤 represents
MI, stroke, HF or death) and 𝑊 the number of event types,
𝑃(𝑡 < 𝑇𝑤 < 𝑡 + ∆𝑡|ℎ𝑖𝑠𝑡𝑜𝑟𝑦 𝑢𝑝 𝑡𝑜 𝑡) = 𝛼𝑤 ∆𝑡 + 𝑜(∆𝑡) for 𝑤 = 1, … , 𝑊
𝑊

𝑃(𝑇𝑤 > 𝑡 + ∆𝑡|ℎ𝑖𝑠𝑡𝑜𝑟𝑦 𝑢𝑝 𝑡𝑜 𝑡) = 1 − ∑ 𝛼𝑤 + 𝑜(∆𝑡)
𝑤=1

We let 𝑠(𝑡) = 𝑃(𝑇𝑀 > 𝑡, 𝑇𝑆 > 𝑡, 𝑇𝐻 > 𝑡, 𝑇𝐷 > 𝑡)
Then,
𝑠 ′ (𝑡) = 𝑠(𝑡)(−𝛼𝑀 −𝛼𝑆 −𝛼𝐻 −𝛼𝐷 )
or equivalently,
𝑠(𝑡) = 𝑒 −(𝛼𝑀 +𝛼𝑆 +𝛼𝐻+𝛼𝐷)𝑡
where 𝑠(𝑡) represents event-free survival of duration 𝑡, 𝑡 ≥ 0; and 𝛼𝑀 , 𝛼𝑆 , 𝛼𝐻 and 𝛼𝐷 represent
the hazard of the next MI, stroke, HF and death, respectively.
We formulate our model on the basis of the above results. The hazards 𝛼𝑀 , 𝛼𝑆 , 𝛼𝐻 and
𝛼𝐷 for each individual are assumed to be dependent on that individual’s event history. A
reasonable rationale for that dependence structure is to assume that there is an intrinsic hazard
for each event (MI, stroke, HF and death). Each nonfatal event then imposes an additional hazard
to itself (its own recurrence) and an additional, almost certainly different, hazard to each of the
other two nonfatal events and death. Death, being the terminal event, has its own intrinsic
hazard plus additional hazards accrued from any nonfatal events (MI, stroke, HF) that have
occurred in an individual’s event history.
Our model therefore updates the hazards 𝛼𝑀 , 𝛼𝑆 , 𝛼𝐻 , and 𝛼𝐷 dynamically as nonfatal
events occur in each individual, with death as the terminal dependent event:
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𝛼𝑀𝑖,𝑗 = 𝑿′ 𝑴𝒊 (𝑡)𝝁𝑴 + 𝑿′ 𝑴𝑴𝒊 (𝑡)𝜷𝑴𝑴 𝑚𝑖𝑗 + 𝑿′ 𝑴𝑺𝒊 (𝑡)𝜷𝑴𝑺 𝑛𝑖𝑗 + 𝑿′ 𝑴𝑯𝒊 (𝑡)𝜷𝑴𝑯 𝑝𝑖𝑗
𝛼𝑆𝑖,𝑗 = 𝑿′ 𝑺𝒊 (𝑡)𝝁𝑺 + 𝑿′ 𝑺𝑴𝒊 (𝑡)𝜷𝑺𝑴 𝑚𝑖𝑗 + 𝑿′ 𝑺𝑺𝒊 (𝑡)𝜷𝑺𝑺 𝑛𝑖𝑗 + 𝑿′ 𝑺𝑯𝒊 (𝑡)𝜷𝑺𝑯 𝑝𝑖𝑗
𝛼𝐻𝑖,𝑗 = 𝑿′ 𝑯𝒊 (𝑡)𝝁𝑯 + 𝑿′ 𝑯𝑴𝒊 (𝑡)𝜷𝑯𝑴 𝑚𝑖𝑗 + 𝑿′ 𝑯𝑺𝒊 (𝑡)𝜷𝑯𝑺 𝑛𝑖𝑗 + 𝑿′ 𝑯𝑯𝒊 (𝑡)𝜷𝑯𝑯 𝑝𝑖𝑗
𝛼𝐷𝑖,𝑗 = 𝑿′ 𝑫𝒊 (𝑡)𝝁𝑫 + 𝑿′ 𝑫𝑴𝒊 (𝑡)𝜷𝑫𝑴 𝑚𝑖𝑗 + 𝑿′ 𝑫𝑺𝒊 (𝑡)𝜷𝑫𝑺 𝑛𝑖𝑗 + 𝑿′ 𝑫𝑯𝒊 (𝑡)𝜷𝑫𝑯 𝑝𝑖𝑗
(1)

where 𝑚𝑖𝑗 , 𝑛𝑖𝑗 , and 𝑝𝑖𝑗 represent the total number of MI’s, strokes and HF’s, respectively that
have occurred prior to event time 𝑡𝑖𝑗 ; 𝑡𝑖𝑗 denotes the time of the 𝑗 𝑡ℎ event in the 𝑖 𝑡ℎ individual.
Our model postulates two main types of hazards: intrinsic and event-type. The intrinsic hazards
for MI, stroke, HF and death are expressed by regression covariate coefficient vectors 𝝁𝑴 , 𝝁𝑺 , 𝝁𝑯
and 𝝁𝑫 associated with covariate vectors 𝑿𝑴𝒊 (𝑡), 𝑿𝑺𝒊 (𝑡), 𝑿𝑯𝒊 (𝑡) and 𝑿𝑫𝒊 (𝑡), respectively. These
intrinsic hazards are the underlying hazards every individual has for MI, stroke, HF and death. The
recurrent parameters denoted by regression covariate coefficient vectors 𝜷𝑴𝑴 , … , 𝜷𝑫𝑯 and
associated with covariate vectors 𝑿𝑴𝑴𝒊 (𝑡), … , 𝑿𝑫𝑯𝒊 (𝑡) represent the event-type hazards, i.e. the
additional hazard for a particular event, nonfatal or fatal, conferred by a particular preceding
nonfatal event. Thus, 𝑿′ • 𝑴𝒊 (𝑡)𝜷• 𝑴 is the additional hazard for any event type (MI, stroke, HF or
death) conferred by preceding MI specifically in the 𝑖th individual with covariates 𝑿• 𝑴𝒊 (𝑡);
𝑿′ • 𝑺𝒊 (𝑡)𝜷• 𝑺 is the additional hazard for any event type (MI, stroke, HF or death) conferred by
preceding stroke specifically in the 𝑖th individual with covariates 𝑿• 𝑺𝒊 (𝑡), and so on. The covariate
vectors are unique to each hazard type and may be time dependent.
2.2 Likelihood function
The likelihood function for 𝑛 subjects is thereby constructed as:
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𝑖
∏𝑛𝑖=1 ∏𝑘𝑗=1
𝑒

−[𝛼𝑀𝑖,𝑗 + 𝛼𝑆𝑖,𝑗 +𝛼𝐻𝑖,𝑗 + 𝛼𝐷𝑖,𝑗 ][𝑡𝑖,𝑗 − 𝑡𝑖,𝑗−1 ]

[𝐼𝑀𝑖,𝑗 ]

[𝛼𝑀𝑖,𝑗 ]

[𝐼𝑆𝑖,𝑗 ]

[𝛼𝑆𝑖,𝑗 ]

[𝛼𝐻𝑖,𝑗 ]

[𝐼𝐻𝑖,𝑗 ]

[𝐼𝐷𝑖,𝑗 ]

[𝛼𝐷𝑖,𝑗 ]

(2)

where 𝑖 = 1, … , 𝑛; such that 𝑛 represents the number of individuals; 𝑗 = 1, … , 𝑘𝑖 , where 𝑘𝑖
denotes the total number of events for the 𝑖 𝑡ℎ individual; 𝑡𝑖𝑗 denotes the 𝑗 𝑡ℎ event time for the
𝑖 𝑡ℎ individual such that 𝑡𝑖𝑗 − 𝑡𝑖,𝑗−1 is the inter-event, or gap time between two successive events
for the 𝑖 𝑡ℎ individual; 𝐼𝑀𝑖,𝑗 is an indicator variable that denotes whether or not MI occurs at 𝑡𝑖,𝑗 ;
𝐼𝑆𝑖,𝑗 is an indicator variable that denotes whether or not stroke occurs at 𝑡𝑖,𝑗 ; 𝐼𝐻𝑖,𝑗 is an indicator
variable that denotes whether or not HF occurs at 𝑡𝑖,𝑗 ; 𝐼𝐷𝑖,𝑗 is an indicator variable that denotes
whether or not death occurs at 𝑡𝑖,𝑗 .

3. Estimation
A modified Newton-Raphson algorithm is used to obtain the maximum likelihood estimates of
the parameters. For computational ease and efficiency, we derived the analytical gradients and
hessian matrix from the log likelihood function. We controlled the step size of every iteration to
ensure that our parameter values stayed within range; each step size was multiplied by 𝑐 starting
with a small value for 𝑐 and gradually increasing 𝑐 closer to 1 as the step size shrank with
increasing iterations. With this approach, we gained the benefits of faster convergence with
Newton-Raphson while avoiding its common pitfalls of cycling, non-convergence or convergence
to the wrong roots. From the hessian matrix at the converged values, we subsequently obtained
the standard errors of our parameter estimates and the corresponding 95% Wald confidence
intervals (CI) of the estimates.

4. Simulation Study
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We conducted a simulation study by simulating datasets comprised of three treatment arms,
mimicking the chlorthalidone, amlodipine, and lisinopril treatment arms from ALLHAT (described
in detail in Section 5) and estimating the parameters. We utilized the regression parameter values
estimated from the ALLHAT data (which we report in Section 5) as the true parameter values for
our simulation study.
To simulate each dataset, we first simulated the initial gap time between time 0
(equivalent to randomization time, with each observation assumed to have no prior events) and
the first event as the 𝑖𝑖𝑑 exponential distribution with rate parameter 𝜆𝑜 equal to the sum of the
intrinsic hazards for each event, i.e.
𝜆𝑜 = 𝑿′ 𝑴𝒊 (𝑡)𝝁𝑴 + 𝑿′ 𝑺𝒊 (𝑡)𝝁𝑺 + 𝑿′ 𝑯𝒊 (𝑡)𝝁𝑯 + 𝑿′ 𝑫𝒊 (𝑡)𝝁𝑫

and mean

1
𝜆𝑜

, where 𝑿′ 𝑴𝒊 (𝑡) = 𝑿′ 𝑺𝒊 (𝑡) = 𝑿′ 𝑯𝒊 (𝑡) = 𝑿′ 𝑫𝒊 (𝑡) = [1, 𝐼𝐴𝑚𝑙𝑜𝑑𝑖𝑝𝑖𝑛𝑒𝑖 , 𝐼𝐿𝑖𝑠𝑖𝑛𝑜𝑝𝑟𝑖𝑙𝑖 ];

𝐼𝐴𝑚𝑙𝑜𝑑𝑖𝑝𝑖𝑛𝑒𝑖 and 𝐼𝐿𝑖𝑠𝑖𝑛𝑜𝑝𝑟𝑖𝑙𝑖 are indicator variables that denote whether or not the 𝑖th individual
is in the amlodipine or lisinopril treatment arms, respectively. The reference group in this
scenario is the chlorthalidone arm. At the end of this initial gap time, we simulated the first event
as a single random sample from a multinomial distribution, with each event type probability
equivalent to its relative proportion, namely
𝑝𝑀 =

𝑿′ 𝑴𝒊 (𝑡)𝝁𝑴
,
𝜆0

𝑿′ 𝑺𝒊 (𝑡)𝝁𝑺
𝑝𝑆 =
,
𝜆0
𝑿′ 𝑯𝒊 (𝑡)𝝁𝑯
𝑝𝐻 =
,
𝜆0
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𝑿′ 𝑫𝒊 (𝑡)𝝁𝑫
𝑝𝐷 =
𝜆0

If a nonfatal event (MI, stroke or HF) occurred, the next gap time (event-free survival) followed
the exponential distribution with updated rate parameter 𝜆1 in accordance with the increased
risk that arose from the new event in the manner described by (1) in Section 2. The subsequent
event was simulated in the same manner as the first, with its event probability equivalent to its
updated relative proportion. The relevant time units for the simulation study are in years.
For each observation, this process continued until death or noninformative right
censoring intervened. We chose a study endpoint 𝑌 = 8 such that each observation in the
simulated dataset that remained alive was automatically right censored at that time.
Furthermore, we simulated another form of noninformative censoring for each observation as
an independent exponential distribution with a separate rate parameter 𝜆𝑐 = 0.05; this
represented study drop-out. Therefore, total follow up time of each observation was
min(𝑇𝐶 , 𝑇𝐷 , 𝑌) where 𝑇𝐶 represents the noninformative censoring time (study drop-out) that
arises from 𝑖𝑖𝑑 exp(𝜆𝑐 ), 𝑇𝐷 represents the time of death if it occurred in the individual, and 𝑌
represents the end of the study. We simulated 501 datasets with the first discarded as burn-in to
yield 500 datasets, each with 30,000 observations (10,000 observations each for chlorthalidone,
amlodipine and lisinopril). We estimated the parameters for each dataset as described in Section
3.
Our simulation study results are in Table 1. For each parameter, we computed the bias as
the average of its estimated parameters minus the true value; the standard error (SE) as the
average of its estimated parameters’ standard errors; the standard deviation (SD) of the
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estimated parameters; and the coverage probability (CP) as the proportion of the simulation runs
whose 95% CI covers the true parameter value. Our results show that the bias is small, the SE of
each parameter is close or equal to the SD and the CP for every parameter is near or at the
nominal value of 95%.

5. Application to ALLHAT
5.1 Study population
The details of ALLHAT’s study population have been described elsewhere. 15-20 Briefly, ALLHAT
was a double-blind, randomized controlled trial that was conducted from February 1994 through
March 2002. Participants were aged 55 or older with hypertension and at least one other
cardiovascular disease (CVD) risk factor (including previous [> 6 months] MI or stroke, left
ventricular hypertrophy [LVH], history of Type 2 diabetes, current cigarette smoking, HDL < 35
mg/dl, or documentation of other atherosclerotic CVD) from 623 centers in North America,
specifically the United States, Canada, Puerto Rico and the US Virgin Islands. A total of 33,357
individuals were randomized to one of three treatment arms: chlorthalidone (𝑁 = 15,255),
amlodipine (𝑁 = 9,048) and lisinopril (𝑁 = 9,054) for planned follow-up of approximately 4 to
8 years. Mean follow-up time was 4.9 years. The primary endpoint was combined: fatal CHD or
nonfatal MI. Major pre-specified secondary outcomes were all-cause mortality, fatal and nonfatal
stroke, combined CHD (the primary outcome, coronary revascularization, and hospitalized
angina), and combined CVD (combined CHD, stroke, other treated angina, HF [fatal, hospitalized,
or treated non-hospitalized] and peripheral arterial disease). ALLHAT was designed to determine
whether the occurrence of fatal CHD or nonfatal MI (the primary endpoint) is lower for high-risk
patients with hypertension treated with a calcium channel blocker (amlodipine) or an ACE
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inhibitor (lisinopril), each compared to diuretic treatment (chlorthalidone). 15-18 A fourth
treatment arm, the α-blocker doxazosin was terminated early when it became apparent that
doxazosin had a very low (< 0.05) probability of having a statistically significant lower incidence
of the primary endpoint compared to chlorthalidone at the end of the study based on the data
up to that point. A second reason was that a large excess of HF became evident in the doxazosin
arm as compared to chlorthalidone.19,20
We applied our method to the in-trial ALLHAT dataset (𝑁 = 33,357) for the nonfatal,
potentially recurrent events MI, stroke and HF, and death as the terminating event. Each
observation in the dataset contained the event times in years from the date of randomization to
the event. If multiple events occurred during the same visit or hospitalization, or within the same
day, for which no further resolution with respect to exact event times was possible, we elected
to assign 0.001 years (8.77 hours) of elapsed time between the two events. With respect to event
order, we assumed that MI preceded HF and stroke, and stroke preceded HF; HF is a common
sequela of MI both acutely and in the long-term. We estimated the parameters and their
attendant standard errors for three different models: (1) base (intercept only) model; (2) intrinsic
hazards covariate model; and (3) intrinsic and recurrent hazards covariate model. We did so using
the statistical inference described in Section 3. We will hereafter refer to the base model, intrinsic
hazards covariate model, and intrinsic and recurrent hazards covariate model as BM, IHCM and
IRHCM, respectively.
5.2 ALLHAT Results
Table 2 displays results for the BM. The intrinsic parameters are all positive and statistically
significant, representing the intrinsic hazards of MI, stroke, HF and death for each observation.
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The intrinsic hazard for death is highest (0.0273 [0.0264 - 0.0281]), more than twice the intrinsic
hazard of MI (0.0106 [0.0101 - 0.0111]), which in turn is higher than HF (0.0066 [0.0062 - 0.0070])
and stroke (0.0063 [0.0059 - 0.0067]). The recurrent parameters are all positive and statistically
significant, implying that each nonfatal event increases the hazard of every event type. For MI,
the recurrent parameter 𝜷𝑀𝑀 is higher (0.0559 [0.0492 - 0.0627]) than 𝜷𝑀𝑆 (0.0127 [0.0070 0.0183]) and 𝜷𝑀𝐻 (0.0154 [0.0102 - 0.0206]). Thus, the risk that a preceding MI imparts to future
MI is higher than the risk that a preceding stroke or HF imparts to future MI. Similarly, the
recurrent parameter 𝜷𝑆𝑆 is much higher (0.0249 [0.0186 - 0.0312]) than 𝜷𝑆𝑀 (0.0038 [0.0014 0.0063]) and 𝜷𝑆𝐻 (0.0049 [0.0018 - 0.0080]). Thus, antecedent stroke imparts a higher risk to
future stroke than it does to future MI or HF. The same trend continues for HF; the recurrent
parameter 𝜷𝐻𝐻 is higher (0.1270 [0.1155 - 0.1384]) than 𝜷𝐻𝑀 (0.0584 [0.0514 - 0.0654]) and
much higher than 𝜷𝐻𝑆 (0.0150 [0.0094 - 0.0205]). Overall, each of these nonfatal events imparts
the greatest risk to its own recurrence, and smaller, but still significant, risks to future occurrence
of other event types. For death, preceding HF imparts the greatest risk (0.0730 [0.0634 - 0.0826]),
followed by stroke (0.0533 [0.0430 - 0.0635]) and then MI (0.0146 [0.0092 - 0.0199]).
Our results for the IHCM are in Table 3. For this model, we introduced the treatment arms
chlorthalidone, amlodipine and lisinopril for the intrinsic hazards and report the results for
chlorthalidone and lisinopril as the reference group, respectively. In both situations, the intercept
parameter corresponds to the intrinsic hazard for that event in the reference group (either
chlorthalidone or lisinopril). Two indicator variables correspond to the remaining two treatment
arms; the covariate parameters of the two indicator variables corresponding to the treatment
arms represent the excess hazard in that treatment arm over that of the reference group. This
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excess hazard may be positive or negative. The sum of the excess hazard and the intrinsic hazard
of the reference group yields the intrinsic hazard for that treatment arm. In this manner, we
compare the results for amlodipine vs chlorthalidone (A vs C), lisinopril vs chlorthalidone (L vs C)
and amlodipine vs lisinopril (A vs L). We provide the intrinsic baseline hazards for all three
treatment arms in the leftmost column. Moreover, we chose to report the excess hazard for the
non-reference group treatment arms this way in order to clearly show whether or not the
difference in the two treatment arms’ hazards from that of the reference group was statistically
significant. Of note, we have omitted the excess hazard for chlorthalidone over lisinopril (C vs L),
because the excess hazard for lisinopril over chlorthalidone (L vs C) is already provided.
With chlorthalidone as the reference group (A vs C and L vs C), we found that the
amlodipine treatment arm has a significant, positive excess intrinsic hazard for HF (0.0029
[0.0019, 0.0039]) over the chlorthalidone treatment arm. With lisinopril as the reference group
(A vs L), the amlodipine arm has a significant, negative excess intrinsic hazard for stroke (-0.0014
[-0.0024, -0.0003]), and a significant, positive excess intrinsic hazard for HF (0.0021 [0.0009,
0.0033]) over lisinopril. As expected, the recurrent parameters, corresponding to the additional
hazards contributed by preceding nonfatal events, remain essentially unchanged from the BM.
Our results for the IRHCM are shown in Table 4. For this model, we introduced the
treatment arms chlorthalidone, amlodipine and lisinopril for both the intrinsic hazards and
recurrent hazards, and we again report the results for chlorthalidone and lisinopril as the
reference group, respectively in a manner analogous to that described for the IHCM.
With chlorthalidone as the reference group (A vs C and L vs C), the amlodipine arm had a
significant, positive excess intrinsic hazard for HF (0.0029 [0.0019, 0.0040]) over chlorthalidone.
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The lisinopril arm had a significant, positive excess hazard for stroke conferred by an antecedent
MI (0.0097 [0.0023, 0.0170]) over chlorthalidone. The lisinopril arm also had a significant,
negative excess hazard for HF conferred by a preceding HF (-0.0337 [-0.0614, -0.0059]) over
chlorthalidone. With lisinopril as the reference group (A vs L), the amlodipine arm had a
significant, negative excess intrinsic hazard for stroke (-0.0013 [-0.0024, -0.0002]) over lisinopril.
The amlodipine arm had a significant, negative excess hazard for stroke conferred by an
antecedent MI (-0.0086 [-0.0164, -0.0008]) over lisinopril. The amlodipine arm also had a
significant, positive excess intrinsic hazard for HF (0.0021 [0.0009, 0.0033]) over lisinopril.
Overall, the IRHCM shows that the amlodipine arm had a significantly higher intrinsic
hazard for HF than both the chlorthalidone and lisinopril arms. The lisinopril arm had a
significantly higher intrinsic hazard for stroke than the amlodipine arm. These two results mirror
that of the IHCM. Moreover, the lisinopril arm had a significantly higher hazard for stroke
conferred by an antecedent MI than both the chlorthalidone and the amlodipine arms. Finally,
the lisinopril arm had a significantly lower hazard for HF conferred by a preceding HF than the
chlorthalidone arm.
5.3 Model Selection and Goodness of Fit
We chose to utilize the Akaike information criterion (AIC) to assess the quality of our models
relative to one another. We present the AIC for all three models in Table 5. The IHCM had the
lowest AIC, followed by the IRHCM; the BM had the highest AIC. These results suggest that the
IHCM provides a better fit to the data than the BM or the IRHCM. The BM performs the least,
suggesting that treatment arm plays at least some role in event occurrence.
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We also wanted to assess our models’ dynamic predictive capabilities, specifically their
ability to predict future event occurrence as events accrue over time. For each model, we chose
to predict event-free survival at 1-year, 2-year, 3-year and 4-year increments for all observations
at baseline (𝑁 = 33,357), observations that had 1 or more events (𝑁 = 3,631), observations
that had 2 or more events (𝑁 = 1,015), observations that had 3 or more events (𝑁 = 392) and
observations that had 4 or more events (𝑁 = 155). Our dataset contained the true survival for
that observation (i.e. a binary result of whether or not that individual had any event, nonfatal or
fatal, within that time frame). We subsequently obtained the estimated area under the curve
(AUC) and its standard error of the resulting receiver operating characteristic (ROC) curve for
each time frame and number of events. If an observation was censored within the time frame of
interest such that true survival for that time frame could not be established, we sampled from a
Bernoulli (𝑝) distribution, with 𝑝 equal to the model’s predicted probability of survival for that
observation. We assigned the resulting value (1 = event-free survival, 0 = event occurred) to that
observation and repeated the sampling process for a total of 100 samples. We then averaged the
AUC estimates and their standard errors to arrive at a final estimated AUC and standard error.
The results for the BM, the IHCM and the IRHCM are presented in Tables 7, 8 and 9, respectively.
The corresponding number and percentage of censored observations is provided in Table 6.
As the BM contains no covariates, all of the observations at baseline (0 events) have the
same probability of event-free survival for any given time frame, which yields a fixed AUC of 0.50
for the 1-year, 2-year, 3-year and 4-year time points. For individuals with 1+ events, there is a
statistically significant increase in AUC (0.58 [0.56, 0.60]) at year 1 which persists to the 4-year
mark. A similar result is seen in individuals with 2+ events; the AUC at 1 year dips slightly ([0.56
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(0.52, 0.59]) from the 1+ individuals, but it catches up by the 3-year mark (0.58 [0.54, 0.62]) and
persists at the 4-year mark. For individuals with 3+ events, the 1-year AUC is higher (0.59 [0.53,
0.64]) than that of individuals with fewer events, and the AUC increases over time elapsed up to
year 3 (0.65 [0.58, 0.73]) after which it dips slightly (0.63 [0.52, 0.73]) at year 4. Observations
with 4+ events have a marked increase in AUC at the 1-year mark (0.65 [0.56, 0.73]) than that of
individuals with fewer events, and their AUC rises steadily over time, peaking at the 4-year mark
(0.71 [0.57, 0.85]). Overall, these results suggest that the number and type of events in an
individual’s clinical history is predictive of future event occurrence.
The IHCM results are similar, and slightly improved from that of the BM. A key feature is
the predictive role of the treatment arms at baseline (0 events); at the 1-year mark, there is a
small but statistically significant rise in AUC (0.52 [0.51, 0.54]) which stems from the amlodipine
arm having an increased hazard of HF over both the chlorthalidone and lisinopril arms. This effect
of amlodipine appears to dissipate over time, as the AUC dips down to 0.50 by the 3-year mark
(0.50 [0.49, 0.51]) and is no longer significant. The remaining results mirror that of the BM, with
the highest AUC in individuals with 4+ events (0.66 [0.57, 0.74]) that increases to 0.71 (0.59, 0.83)
by the 3-year time point.
The IRHCM is similar to the IHCM, with a slightly increased AUC of individuals with 2+
events starting at 1 year, and individuals with 3+ events at the 2-year mark, when compared to
the IHCM. This most likely reflects the treatment arms effects on recurrent events. For the
individuals with 4+ events, the AUC for the IRHCM is slightly lower than that of both the IHCM
and the BM at each time point. Overall, the results for all three models suggest that hazards
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accrued from events as they occur play a major role in dynamic risk, and the treatment arm plays
a relatively minor role in prediction of future event occurrence and recurrence.

6. Discussion
In this work, we presented a multi-type recurrent events model with dependent termination in a
competing risk framework that provides a dynamic risk trajectory over time. Our model is well
suited for longitudinal studies, which often feature recurrent events. The model provides the
baseline hazard, or absolute risk, for each competing event type at any desired time point and
incorporates the previous types and numbers of events in that individual in doing so. This allows
a straightforward quantification of the relationship, if any, between different event types; the
recurrent event parameters represent the additional hazard that a preceding nonfatal event
confers to the event of interest. If this hazard is zero, it suggests a lack of association, or
correlation, between those event types.
Our simulation study, patterned after the IRHCM, introduced covariates to the intrinsic
hazards and the recurrent hazards. The simulation showed that our model can handle covariates
for both the intrinsic and recurrent parameters, which results in a fairly large number of
parameters, with relative ease. This has the potential to yield unique and important insights. Our
work was motivated by the ALLHAT study, and our model was developed in the setting of multitype recurrent events in CVD that are associated with one another based on the known
pathophysiology of CVD. Our model, when applied to the in-trial ALLHAT study, yielded results
consistent with the main ALLHAT findings, particularly the increased intrinsic hazard for nonfatal
HF in the amlodipine arm over that of both the chlorthalidone and lisinopril arms, and the
increased hazard for nonfatal stroke in the lisinopril arm over that of amlodipine. 16,17
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Additionally, the IRHCM yielded new insights from the ALLHAT study in terms of treatment arm
effects on recurrent events. In particular, the lisinopril arm had a lower hazard of HF conferred
by a preceding HF compared to the chlorthalidone arm. This suggests that individuals with known
HF may receive a benefit from lisinopril over chlorthalidone in preventing future HF events. ACE
inhibitors are a first line agent for HF management, partly because they have been shown to
reduce hospitalizations for recurrent HF21 and our results provide further support for the role of
ACE inhibitors in reducing recurrent HF risk.
A unique aspect of our method is that it provides a dynamic risk trajectory for an
individual based on their event history, and that risk is updated with each event as it occurs. This
can yield potent predictive capabilities for future events and can direct optimal strategies for
event-free survival tailored to that individual’s clinical profile. We have already demonstrated
that our models have good predictive ability for event-free survival for individuals with 4+ events
from the 3-year mark onward, and reasonable prediction of event-free survival for individuals
with 3+ events from the 3-year mark onward. In that regard, the BM is surprisingly competitive
with both the IHCM and the IRHCM in terms of its ability to predictive future event occurrence
over time. There was little difference in predictive ability between the models, which suggests
that the hazards accrued over time by events as they occur play the dominant role in predicting
event-free survival. This underscores a central tenet of our methodology, which is that
accumulated events impart hazards that are cumulative, updated with each event occurrence
over time. Moreover, we applied our model to the full in-trial ALLHAT dataset with no missing
observations, another key strength of our study.
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We acknowledge two limitations. First, the three models we applied to the ALLHAT data
take between 5-10 minutes to converge, which is a reasonable time frame. For our simulation
study, we deliberately chose to simulate each dataset (𝑁 = 30,000) to approximate the size of
ALLHAT, so the 500 simulation runs took several days to complete. This can be addressed by
simulating smaller datasets and/or fewer simulation runs, or the use of a supercomputer. A
second limitation of our study is the somewhat large proportion of right censored observations
for the individuals with 1+, 2+, 3+ and 4+ events starting at the 3-year mark. The handling of
censored observations is a ubiquitous problem in survival analysis with manifold approaches. We
elected to address it via random sampling from our model’s predicted survival probability.
Alternative approaches to censored observations in this setting would be an interesting and
worthwhile future research endeavor.
Lastly, we anticipate a marked enhancement of our model’s dynamic risk prediction
capabilities with the incorporation of additional suitable covariates into both the intrinsic hazards
and recurrent hazards. This will involve tailored model building and selection involving a
potentially large number of parameters. We also wish to explore possible treatment arm
differences for specific subgroups including age, gender and race which involve interaction terms
as covariates in our models. We will address these important queries in our next paper, which
will provide further insights into the recurrent nature of CVD.
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Table 1. Simulation study.

MI

Stroke

Parameter
𝝁𝑴
C
A
L
𝜷𝑴𝑴
C
A
L
𝜷𝑴𝑺
C
A
L
𝜷𝑴𝑯
C
A
L

Truth

Estimate

Bias

SE

SD

CP

0.0109
-0.0005
-0.0007

0.0110
-0.0005
-0.0008

0.0001
<0.0001
-0.0001

0.0004
0.0006
0.0006

0.0004
0.0006
0.0006

0.954
0.952
0.952

0.0588
-0.0056
-0.0055

0.0590
-0.0059
-0.0060

0.0002
-0.0003
-0.0005

0.0053
0.0074
0.0075

0.0051
0.0074
0.0071

0.954
0.950
0.958

0.0135
0.0019
-0.0043

0.0138
0.0021
-0.0047

0.0003
0.0002
-0.0004

0.0046
0.0068
0.0060

0.0047
0.0068
0.0061

0.932
0.944
0.954

0.0123
0.0075
0.0027

0.0122
0.0078
0.0029

-0.0001
0.0003
0.0002

0.0039
0.0055
0.0057

0.0040
0.0053
0.0055

0.946
0.960
0.960

C
A
L

0.0063
-0.0006
0.0007

0.0063
-0.0006
0.0007

<0.0001
<0.0001
<0.0001

0.0003
0.0005
0.0005

0.0003
0.0005
0.0005

0.944
0.950
0.926

C
A
L

0.0013
0.0011
0.0097

0.0013
0.0010
0.0098

<0.0001
-0.0001
0.0001

0.0016
0.0025
0.0032

0.0018
0.0025
0.0033

0.930
0.956
0.950

C
A
L

0.0248
0.0022
-0.0020

0.0248
0.0023
-0.0018

<0.0001
0.0001
0.0002

0.0050
0.0074
0.0069

0.0048
0.0074
0.0070

0.958
0.940
0.946

C
A
L

0.0031
0.0061
-0.0008

0.0033
0.0058
-0.0012

0.0002
-0.0003
-0.0004

0.0022
0.0034
0.0032

0.0025
0.0035
0.0036

0.918
0.930
0.912

C
A
L

0.0056
0.0029
0.0008

0.0055
0.0029
0.0008

-0.0001
<0.0001
<0.0001

0.0003
0.0005
0.0005

0.0003
0.0005
0.0005

0.936
0.960
0.958

C
A

0.0522
0.0161

0.0518
0.0165

-0.0004
0.0004

0.0050
0.0078

0.0051
0.0078

0.938
0.938

𝝁𝑺

𝜷𝑺𝑴

𝜷𝑺𝑺

𝜷𝑺𝑯

HF

𝝁𝑯

𝜷𝑯𝑴
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L

0.0079

0.0082

0.0003

0.0076

0.0073

0.966

C
A
L

0.0175
-0.0082
-0.0019

0.0176
-0.0081
-0.0019

0.0001
0.0001
<0.0001

0.0046
0.0062
0.0062

0.0048
0.0063
0.0064

0.932
0.960
0.940

C
A
L

0.1431
-0.0213
-0.0337

0.1435
-0.0217
-0.0346

0.0004
-0.0004
-0.0009

0.0100
0.0127
0.0132

0.0097
0.0123
0.0130

0.958
0.952
0.952

C
A
L

0.0279
-0.0015
-0.0008

0.0279
-0.0016
-0.0008

<0.0001
-0.0001
<0.0001

0.0007
0.0010
0.0010

0.0007
0.0010
0.0010

0.958
0.966
0.948

C
A
L

0.0163
-0.0029
-0.0039

0.0167
-0.0033
-0.0042

0.0004
-0.0004
-0.0003

0.0042
0.0059
0.0060

0.0043
0.0062
0.0061

0.942
0.944
0.956

C
A
L

0.0540
-0.0017
-0.0011

0.0541
-0.0012
-0.0008

0.0001
0.0005
0.0003

0.0084
0.0119
0.0114

0.0084
0.0121
0.0115

0.962
0.956
0.952

𝜷𝑯𝑺

𝜷𝑯𝑯

Death

𝝁𝑫

𝜷𝑫𝑴

𝜷𝑫𝑺

𝜷𝑫𝑯
C
0.0752
0.0754
0.0002
0.0080
0.0080
A
-0.0096
-0.0095
0.0001
0.0102
0.0103
L
0.0039
0.0040
0.0001
0.0112
0.0109
SE, standard error; SD, standard deviation; CP, coverage probability; C, chlorthalidone;
amlodipine; L, lisinopril.
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0.932
0.944
0.954
A,

Table 2. Base (intercept only) model.

Parameter
𝝁𝑴
𝜷𝑴𝑴
𝜷𝑴𝑺
𝜷𝑴𝑯

Estimate (95% CI)
0.0106 (0.0101, 0.0111)
0.0559 (0.0492, 0.0627)
0.0127 (0.0070, 0.0183)
0.0154 (0.0102, 0.0206)

Stroke

𝝁𝑺
𝜷𝑺𝑴
𝜷𝑺𝑺
𝜷𝑺𝑯

0.0063 (0.0059, 0.0067)
0.0038 (0.0014, 0.0063)
0.0249 (0.0186, 0.0312)
0.0049 (0.0018, 0.0080)

HF

𝝁𝑯
𝜷𝑯𝑴
𝜷𝑯𝑺
𝜷𝑯𝑯

0.0066 (0.0062, 0.0070)
0.0584 (0.0514, 0.0654)
0.0150 (0.0094, 0.0205)
0.1270 (0.1155, 0.1384)

Death

𝝁𝑫
𝜷𝑫𝑴
𝜷𝑫𝑺
𝜷𝑫𝑯

0.0273 (0.0264, 0.0281)
0.0146 (0.0092, 0.0199)
0.0533 (0.0430, 0.0635)
0.0730 (0.0634, 0.0826)

MI
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Table 3. Intrinsic hazards covariate model.
Baseline hazard

MI

Stroke

HF

Parameter
𝝁𝑴
C
A
L

Estimate (95% CI)
0.0109 (0.0102, 0.0117)
0.0105 (0.0096, 0.0115)
0.0102 (0.0092, 0.0111)

𝜷𝑴𝑴
𝜷𝑴𝑺
𝜷𝑴𝑯

0.0559 (0.0492, 0.0626)
0.0127 (0.0070, 0.0183)
0.0155 (0.0103, 0.0206)

𝝁𝑺
C
A
L

0.0062 (0.0056, 0.0068)
0.0057 (0.0050, 0.0065)
0.0071 (0.0063, 0.0079)

𝜷𝑺𝑴
𝜷𝑺𝑺
𝜷𝑺𝑯

0.0037 (0.0012, 0.0062)
0.0249 (0.0186, 0.0312)
0.0050 (0.0019, 0.0081)

𝝁𝑯
C
A
L

0.0056 (0.0050, 0.0061)
0.0085 (0.0076, 0.0093)
0.0064 (0.0056, 0.0071)

𝜷𝑯𝑴

0.0583 (0.0513, 0.0653)

Excess hazard
Reference Group:
Chlorthalidone
(A vs C and L vs C)
Estimate (95% CI)

-0.0004 (-0.0017, 0.0008)
-0.0008 (-0.0020, 0.0005)

-0.0005 (-0.0014, 0.0004)
0.0009 (-0.0001, 0.0019)

0.0039)*

0.0029 (0.0019,
0.0008 (-0.0001, 0.0017)
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Reference Group:
Lisinopril
(A vs L)
Estimate (95% CI)

-0.0003 (-0.0010, 0.0017)

--0.0014 (-0.0024, -0.0003)*

-0.0021 (0.0009, 0.0033)*

𝜷𝑯𝑺
𝜷𝑯𝑯

0.0152 (0.0096, 0.0207)
0.1269 (0.1154, 0.1383)

𝝁𝑫
C
0.0279 (0.0267, 0.0291)
-A
0.0263 (0.0248, 0.0278) -0.0016 (-0.0036, 0.0003)
-0.0008 (-0.0030, 0.0014)
L
0.0271 (0.0255, 0.0287) -0.0008 (-0.0028, 0.0011)
𝜷𝑫𝑴
0.0145 (0.0091, 0.0199)
𝜷𝑫𝑺
0.0533 (0.0430, 0.0635)
𝜷𝑫𝑯
0.0731 (0.0635, 0.0826)
*statistically significant excess hazard over that of the reference group
C, the baseline hazard for chlorthalidone (left column); A, the baseline hazard for amlodipine (left column), the excess hazard over
chlorthalidone for amlodipine (middle column) and excess hazard over lisinopril for amlodipine (right column); L, the baseline hazard
for lisinopril (left column) and the excess hazard over chlorthalidone for lisinopril (middle column).
Death
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Table 4. Intrinsic and recurrent hazards covariate model.
Baseline hazard

MI

Stroke

Parameter
𝝁𝑴
C
A
L
𝜷𝑴𝑴
C
A
L
𝜷𝑴𝑺
C
A
L
𝜷𝑴𝑯
C
A
L
𝝁𝑺
C
A
L
𝜷𝑺𝑴
C
A

Estimate (95% CI)
0.0109 (0.0102, 0.0117)
0.0105 (0.0095, 0.0115)
0.0102 (0.0093, 0.0112)

Excess hazard
Reference Group:
Chlorthalidone
(A vs C and L vs C)
Estimate (95% CI)

-0.0005 (-0.0017, 0.0008)
-0.0007 (-0.0020, 0.0005)

0.0588 (0.0489, 0.0688)
0.0532 (0.0403, 0.0661)
0.0533 (0.0403, 0.0663)

-0.0056 (-0.0219, 0.0107)
-0.0055 (-0.0219, 0.0108)

0.0135 (0.0050, 0.0220)
0.0154 (0.0033, 0.0275)
0.0092 (-0.0002, 0.0186)

0.0019 (-0.0129, 0.0167)
-0.0043 (-0.0170, 0.0083)

0.0123 (0.0047, 0.0199)
0.0198 (0.0099, 0.0297)
0.0149 (0.0053, 0.0246)

0.0075 (-0.0049, 0.0200)
0.0027 (-0.0096, 0.0149)

0.0063 (0.0057, 0.0069)
0.0057 (0.0050, 0.0064)
0.0070 (0.0062, 0.0078)

-0.0006 (-0.0015, 0.0003)
0.0007 (-0.0003, 0.0017)

0.0013 (-0.0016, 0.0042)
0.0024 (-0.0015, 0.0063)

0.0011 (-0.0038, 0.0059)
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Reference Group:
Lisinopril
(A vs L)
Estimate (95% CI)

-0.0003 (-0.0011, 0.0016)

--0.0001 (-0.0183, 0.0182)

-0.0062 (-0.0091, 0.0215)

-0.0049 (-0.0089, 0.0186)

--0.0013 (-0.0024, -0.0002)*

--0.0086 (-0.0164, -0.0008)*

L
𝜷𝑺𝑺
C
A
L
𝜷𝑺𝑯
C
A
L
HF

Death

𝝁𝑯
C
A
L
𝜷𝑯𝑴
C
A
L
𝜷𝑯𝑺
C
A
L
𝜷𝑯𝑯
C
A
L
𝝁𝑫
C
A
L

0.0110 (0.0042, 0.0177)

0.0097 (0.0023, 0.0170)*

0.0248 (0.0154, 0.0342)
0.0270 (0.0140, 0.0401)
0.0228 (0.0117, 0.0339)

0.0022 (-0.0139, 0.0183)
-0.0020 (-0.0165, 0.0126)

0.0031 (-0.0015, 0.0077)
0.0093 (0.0028, 0.0157)
0.0023 (-0.0025, 0.0072)

0.0061 (-0.0018, 0.0141)
-0.0008 (-0.0075, 0.0059)

0.0056 (0.0050, 0.0061)
0.0085 (0.0076, 0.0093)
0.0064 (0.0056, 0.0071)

0.0029 (0.0019, 0.0040)*
0.0008 (-0.0001, 0.0018)

0.0522 (0.0427, 0.0617)
0.0683 (0.0533, 0.0833)
0.0601 (0.0463, 0.0739)

0.0161 (-0.0016, 0.0338)
0.0079 (-0.0089, 0.0246)

0.0175 (0.0089, 0.0261)
0.0094 (-0.0010, 0.0198)
0.0156 (0.0057, 0.0255)

-0.0082 (-0.0217, 0.0053)
-0.0019 (-0.0150, 0.0112)

0.1431 (0.1239, 0.1623)
0.1218 (0.1019, 0.1418)
0.1094 (0.0894, 0.1294)

-0.0213 (-0.0490, 0.0064)
-0.0337 (-0.0614, -0.0059)*

0.0279 (0.0266, 0.0291)
0.0264 (0.0248, 0.0279)
0.0271 (0.0255, 0.0287)

-0.0015 (-0.0035, 0.0005)
-0.0008 (-0.0028, 0.0012)
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-0.0042 (-0.0130, 0.0213)

-0.0069 (-0.0011, 0.0150)

-0.0021 (0.0009, 0.0033)*

-0.0082 (-0.0121, 0.0285)

--0.0062 (-0.0206, 0.0081)

-0.0124 (-0.0158, 0.0406)

--0.0007 (-0.0029, 0.0015)

𝜷𝑫𝑴
C
0.0163 (0.0082, 0.0244)
-A
0.0134 (0.0036, 0.0231)
-0.0029 (-0.0156, 0.0098)
0.0010 (-0.0133, 0.0153)
L
0.0124 (0.0019, 0.0228)
-0.0039 (-0.0172, 0.0093)
𝜷𝑫𝑺
C
0.0540 (0.0386, 0.0695)
-A
0.0524 (0.0318, 0.0729)
-0.0017 (-0.0274, 0.0240)
-0.0006 (-0.0282, 0.0269)
L
0.0530 (0.0346, 0.0714)
-0.0011 (-0.0251, 0.0229)
𝜷𝑫𝑯
C
0.0752 (0.0596, 0.0907)
-A
0.0655 (0.0496, 0.0815)
-0.0096 (-0.0319, 0.0127)
-0.0135 (-0.0380, 0.0110)
L
0.0790 (0.0605, 0.0976)
0.0039 (-0.0203, 0.0281)
*statistically significant excess hazard over that of the reference group
C, the baseline hazard for the corresponding category (intrinsic, recurrent) for chlorthalidone (left column); A, the baseline hazard for
the corresponding category (intrinsic, recurrent) for amlodipine (left column), the excess hazard over chlorthalidone for the
corresponding category (intrinsic, recurrent) for amlodipine (middle column) and the excess hazard over lisinopril for the
corresponding category (intrinsic, recurrent) for amlodipine (right column); L, the baseline hazard for the corresponding category
(intrinsic, recurrent) for lisinopril (left column) and the excess hazard over chlorthalidone for lisinopril (middle column).
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Table 5. Model AIC.

Number of
parameters
AIC

BM

IHCM

IRHCM

16

24

48

98349.81

98321.82

98342.98
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Table 6. Number and percentage of censored observations.
Year

1
2
3
4

0 events
N=33,357
n (%)
111 (0.33)
141 (0.42)
206 (0.62)
2426 (7.27)

1+ events
N=3,631
n (%)
385 (10.60)
845 (23.27)
1241 (34.18)
1592 (43.84)

2+ events
N=1,015
n (%)
126 (12.41)
229 (22.56)
331 (32.61)
390 (38.42)
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3+ events
N=392
n (%)
52 (13.27)
87 (22.19)
120 (30.61)
143 (36.48)

4+ events
N=155
n (%)
24 (15.48)
32 (20.65)
37 (23.87)
45 (29.03)

Table 7. Area under the curve for the BM.
Year
1
2
3
4

0 events
N=33,357
0.50
–
0.50
–
0.50
–
0.50
–

1+ events
N=3,631
0.58
(0.56, 0.60)
0.59
(0.57, 0.60)
0.58
(0.56, 0.60)
0.58
(0.56, 0.60)

2+ events
N=1,015
0.56
(0.52, 0.59)
0.57
(0.54, 0.61)
0.58
(0.54, 0.62)
0.58
(0.54, 0.63)

43

3+ events
N=392
0.59
(0.53, 0.64)
0.62
(0.56, 0.68)
0.65
(0.58, 0.73)
0.63
(0.52, 0.73)

4+ events
N=155
0.65
(0.56, 0.73)
0.67
(0.56, 0.77)
0.70
(0.57, 0.82)
0.71
(0.57, 0.85)

Table 8. Area under the curve for the IHCM.
Year
1
2
3
4

0 events
N=33,357
0.52
(0.51, 0.54)
0.51
(0.50, 0.52)
0.50
(0.49, 0.51)
0.50
(0.49, 0.51)

1+ events
N=3,631
0.59
(0.56, 0.61)
0.59
(0.57, 0.61)
0.58
(0.56, 0.60)
0.58
(0.56, 0.60)

2+ events
N=1,015
0.55
(0.52, 0.59)
0.57
(0.53, 0.60)
0.58
(0.54, 0.62)
0.58
(0.53, 0.63)
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3+ events
N=392
0.59
(0.53, 0.64)
0.61
(0.55, 0.68)
0.65
(0.57, 0.72)
0.62
(0.51, 0.72)

4+ events
N=155
0.66
(0.57, 0.74)
0.67
(0.57, 0.78)
0.71
(0.59, 0.83)
0.70
(0.55, 0.85)

Table 9. Area under the curve for the IRHCM.
Year
1
2
3
4

0 events
N=33,357
0.52
(0.51, 0.54)
0.51
(0.50, 0.52)
0.50
(0.49, 0.51)
0.50
(0.49, 0.51)

1+ events
N=3,631
0.59
(0.57, 0.61)
0.59
(0.57, 0.61)
0.58
(0.57, 0.60)
0.59
(0.57, 0.61)

2+ events
N=1,015
0.57
(0.53, 0.60)
0.58
(0.54, 0.61)
0.59
(0.55, 0.63)
0.60
(0.55, 0.64)
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3+ events
N=392
0.59
(0.54, 0.65)
0.62
(0.55, 0.68)
0.65
(0.58, 0.73)
0.62
(0.52, 0.72)

4+ events
N=155
0.63
(0.54, 0.72)
0.66
(0.55, 0.77)
0.69
(0.55, 0.83)
0.70
(0.55, 0.85)

CHAPTER 3: JOURNAL ARTICLE 2
Competing risks of recurrent cardiovascular events with all-cause mortality
ABSTRACT
Despite a number of established risk scores for cardiovascular disease (CVD), none to date
provide a risk assessment of multiple, competing CVD outcomes that incorporates number and
type of CVD events along with clinical profile. We extend our previously reported multi-type
recurrent events model to develop several models (IHCM 1, IHCM 2 and IRHCM) that were
applied to the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT) study. IHCM 1 and IRHCM quantified the dynamic risks of nonfatal myocardial infarction
(MI), stroke and heart failure (HF), and all-cause mortality (death) given risk factors for each
event-type, with risks updated after every event occurrence. IHCM2 examined interactions
between selected CVD risk factors and treatment arms. Baseline age, diabetes, history of MI or
stroke, kidney disease and smoking are risk factors common to all 4 event-types. Diabetes and
kidney disease each impart more risk to death than nonfatal events. Atrial fibrillation confers
more risk to HF than it does to death or stroke. IHCM 2 showed significant interactions between
diabetes and amlodipine for HF; black race and lisinopril for stroke; atrial fibrillation and
amlodipine and lisinopril for death. IRHCM outperformed IHCM 1 in predicting event-free
survival, and both models performed best at baseline (0 events) and in individuals with 4+ events.
IHCM 1 and IRHCM are useful in identifying and quantifying risk factors for CVD and predicting
risk trajectory and event-free survival, with significant potential to develop into a dynamic CVD
risk score that guides individualized therapeutic management.
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BACKGROUND
Major risk factors for cardiovascular disease (CVD) are well established.1-3 The
Framingham risk score is widely used in clinical practice and epidemiological research 2,4; it was
originally developed to calculate 10-year risks of coronary heart disease (CHD) utilizing several of
these established risk factors: age, dyslipidemia, blood pressure, diabetes, and smoking. 2,4
Subsequently, cerebrovascular events, peripheral artery disease (PAD) and heart failure (HF)
were added to formulate a more general CVD risk assessment tool, expanding the Framingham
risk score to include 10-year risks of CVD 2,5.
In spite of the ubiquitous use of risk scores to predict CVD outcomes and preferentially
target individuals at particular risk of CVD events in the short and long term, there has not been
to our knowledge a risk score or risk assessment of CVD outcomes that incorporate specific
number and types of CVD events in an individual’s past medical history in conjunction with their
clinical and demographic profile. In our previous work, 6 we introduced a dynamic competing risk
model for multi-type recurrent events that is uniquely tailored to quantify baseline hazard, or
absolute risk, of future CVD events given the individual’s particular event history e.g. a personal
history of nonfatal myocardial infarction (MI), stroke and 2 episodes of HF. Recurrent CVD events
are a common feature of longitudinal studies, and it is known that each CVD event imparts risk
for future CVD events.1 Therefore, the gap time, or time between CVD events or between a CVD
event and death tends to decrease, particularly in the absence of intervention. Our model
hypothesizes that each nonfatal CVD event imparts a particular risk to the future occurrence of
each type of nonfatal CVD event (including its own recurrence) and a different, also particular,
risk of death. The nonfatal CVD events serve as competing risks, with death being a competing
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risk as well as a dependent terminal event after which no further events can occur. Moreover,
our model assumes that the risk imparted by a particular CVD event on another CVD outcome is
explained by a unique set of covariates, possibly time-dependent.
This approach yields valuable clinical insights to the nature of CVD and CVD mortality and
the particular risk factors that are most relevant in preventing or ameliorating first occurrence of
a CVD event, future occurrence or recurrence of CVD events, and death. Our model would show
that certain risk factors such as diabetes, renal insufficiency and atrial fibrillation may pose
greater risks to certain CVD events over others. Furthermore, head to head comparisons between
drug regimens and other medical therapeutic interventions in their ability to thwart the incidence
and recurrence of CVD and CVD-related death can be made. The global disease burden of CVD is
enormous and cannot be overstated.7 CVD is the leading cause of death worldwide and its
chronic, recurrent nature and often devastating consequences including lifelong disability and
death make such a detailed CVD risk assessment as provided by our model an urgent clinical and
public health imperative.1,7
Our recurrent events statistical model described in our previous paper 6 was motivated
by the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
study. In this paper, we return to the ALLHAT dataset to extend our methodology to include
relevant clinical covariates for the intrinsic hazard every individual has for CVD events and death.
We will further extend our method to select appropriate covariates for recurrent hazards, i.e. the
hazard imparted by a CVD event for future CVD events. These two aforementioned models are
extensions of the intrinsic hazards covariate model (IHCM) and intrinsic and recurrent hazards
covariate model (IRHCM) described in our previous work.6 Interactions between selected
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clinically important variables and treatment arms will be explored as another variant of the IHCM
to examine heterogeneity of treatment effects between subgroups for intrinsic hazards of CVD
outcomes.
METHODS
Study Population
ALLHAT’s study population has been described elsewhere.8,9 Briefly, ALLHAT was a
double-blind, randomized controlled trial that was conducted from February 1994 through
March 2002. Participants were aged 55 or older with hypertension and at least one additional
CVD risk factor [including previous (> 6 months) MI or stroke, left ventricular hypertrophy (LVH),
history of Type 2 diabetes (hereafter, diabetes), current cigarette smoking, high-density
lipoprotein (HDL) < 35 mg/dl, or documentation of other atherosclerotic CVD (OASCVD)] from
623 centers in North America, specifically the United States, Canada, Puerto Rico and the US
Virgin Islands. A total of 33,357 individuals were randomized to one of three treatment arms:
chlorthalidone (𝑁 = 15,255), amlodipine (𝑁 = 9,048) and lisinopril (𝑁 = 9,054) for planned
follow-up of approximately 4 to 8 years. Mean follow-up time was 4.9 years. The primary
endpoint was fatal CHD or nonfatal MI. Major pre-specified secondary outcomes were all-cause
mortality, fatal and nonfatal stroke, combined CHD (the primary outcome, coronary
revascularization, and hospitalized angina), and combined CVD [combined CHD, stroke, other
treated angina, HF (fatal, hospitalized, or treated non-hospitalized) and PAD]. ALLHAT was
designed to determine whether the occurrence of fatal CHD or nonfatal MI (the primary
endpoint) is lower for high-risk patients with hypertension treated with a calcium channel blocker
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(amlodipine) or an ACE inhibitor (lisinopril), each compared to diuretic treatment
(chlorthalidone).8,9
Statistical model
Since our model has been described at length in our previous work,

6

we will quickly

recapitulate its salient aspects here before we proceed to describe the IHCM and IRHCM models
that comprise the bulk of our statistical analyses. We let 𝛼𝑀 , 𝛼𝑆 , 𝛼𝐻 and 𝛼𝐷 denote the hazards
(risks) for nonfatal MI, nonfatal stroke, nonfatal HF, and death from any cause (hereafter referred
to as death), respectively. From this juncture, MI, stroke and HF will be assumed nonfatal unless
otherwise noted. Each of the hazards 𝛼𝑀 , 𝛼𝑆 , 𝛼𝐻 and 𝛼𝐷 are assumed to be dependent on that
individual’s event history. We further assume that there is an intrinsic hazard for each event (MI,
stroke, HF and death). Each nonfatal event then imposes an additional hazard to itself (its own
recurrence) and an additional, different hazard to each of the other two nonfatal events and
death. Death, being the terminal event, has its own intrinsic hazard plus additional hazards
accrued from any nonfatal events (MI, stroke, HF) that have occurred up to the point of interest.
Throughout this paper, we will use the terms hazard, risk and absolute risk interchangeably.
Our model therefore updates the hazards 𝛼𝑀 , 𝛼𝑆 , 𝛼𝐻 , and 𝛼𝐷 dynamically as nonfatal
events occur in each individual, with death as the terminal dependent event:
𝛼𝑀𝑖,𝑗 = 𝑿′ 𝑴𝒊 (𝑡)𝝁𝑴 + 𝑿′ 𝑴𝑴𝒊 (𝑡)𝜷𝑴𝑴 𝑚𝑖𝑗 + 𝑿′ 𝑴𝑺𝒊 (𝑡)𝜷𝑴𝑺 𝑛𝑖𝑗 + 𝑿′ 𝑴𝑯𝒊 (𝑡)𝜷𝑴𝑯 𝑝𝑖𝑗
𝛼𝑆𝑖,𝑗 = 𝑿′ 𝑺𝒊 (𝑡)𝝁𝑺 + 𝑿′ 𝑺𝑴𝒊 (𝑡)𝜷𝑺𝑴 𝑚𝑖𝑗 + 𝑿′ 𝑺𝑺𝒊 (𝑡)𝜷𝑺𝑺 𝑛𝑖𝑗 + 𝑿′ 𝑺𝑯𝒊 (𝑡)𝜷𝑺𝑯 𝑝𝑖𝑗
𝛼𝐻𝑖,𝑗 = 𝑿′ 𝑯𝒊 (𝑡)𝝁𝑯 + 𝑿′ 𝑯𝑴𝒊 (𝑡)𝜷𝑯𝑴 𝑚𝑖𝑗 + 𝑿′ 𝑯𝑺𝒊 (𝑡)𝜷𝑯𝑺 𝑛𝑖𝑗 + 𝑿′ 𝑯𝑯𝒊 (𝑡)𝜷𝑯𝑯 𝑝𝑖𝑗
𝛼𝐷𝑖,𝑗 = 𝑿′ 𝑫𝒊 (𝑡)𝝁𝑫 + 𝑿′ 𝑫𝑴𝒊 (𝑡)𝜷𝑫𝑴 𝑚𝑖𝑗 + 𝑿′ 𝑫𝑺𝒊 (𝑡)𝜷𝑫𝑺 𝑛𝑖𝑗 + 𝑿′ 𝑫𝑯𝒊 (𝑡)𝜷𝑫𝑯 𝑝𝑖𝑗
(1)
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where 𝑚𝑖𝑗 , 𝑛𝑖𝑗 , and 𝑝𝑖𝑗 represent the total number of MI’s, strokes and HF’s, respectively that
have occurred prior to event time 𝑡𝑖𝑗 ; 𝑡𝑖𝑗 denotes the time of the 𝑗 𝑡ℎ event in the 𝑖 𝑡ℎ individual.
Our model delineates two main types of hazards: intrinsic and event-type. The intrinsic hazards
for MI, stroke, HF and death are expressed by regression covariate coefficient vectors 𝝁𝑴 , 𝝁𝑺 , 𝝁𝑯
and 𝝁𝑫 associated with covariate vectors 𝑿𝑴𝒊 (𝑡), 𝑿𝑺𝒊 (𝑡), 𝑿𝑯𝒊 (𝑡) and 𝑿𝑫𝒊 (𝑡), respectively. These
intrinsic hazards are the underlying hazards every individual has for those events. The recurrent
parameters denoted by regression covariate coefficient vectors 𝜷𝑴𝑴 , … , 𝜷𝑫𝑯 and associated
with covariate vectors 𝑿𝑴𝑴𝒊 (𝑡), … , 𝑿𝑫𝑯𝒊 (𝑡) represent the event-type hazards, i.e. the additional
hazard for a particular event, nonfatal or fatal, conferred by a particular preceding nonfatal
event. Thus, 𝑿′ • 𝑴𝒊 (𝑡)𝜷• 𝑴 is the additional hazard for any event type (MI, stroke, HF or death)
conferred by preceding MI specifically in the 𝑖th individual with covariates 𝑿• 𝑴𝒊 (𝑡); 𝑿′ • 𝑺𝒊 (𝑡)𝜷• 𝑺
is the additional hazard for any event type (MI, stroke, HF or death) conferred by preceding stroke
specifically in the 𝑖th individual with covariates 𝑿• 𝑺𝒊 (𝑡), and so on. The covariate vectors are
unique to each hazard type and may be time dependent.
Thus, each hazard can be characterized by a unique, possibly time dependent, set of
covariates which results in each individual having a tailored hazard for every CVD event and
death, at baseline. These hazards update dynamically as the person moves through time and
possibly accrues further CVD events. The IHCM and IRHCM are two models that arise naturally
from the above rationale. For the IHCM, the intrinsic hazards contain covariates whereas the
recurrent hazards do not contain covariates, i.e. they are left as intercepts. For the IRHCM, both
the intrinsic and recurrent hazards may contain covariates. For IHCM and IRHCM and the
purposes of this paper, all of the estimated parameters represent 1-year hazards; thus, they are
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equivalent to the annual incidence of MI, stroke, HF and death. All of our statistical analyses were
carried out in R 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria); parameter
estimations were carried out by a modified Newton-Raphson algorithm described in our previous
work 6 and independently verified by R’s optim function (provided in the base package) using the
BFGS algorithm.
Statistical analyses
The ICHM is the more parsimonious model and we report two separate sub-analyses of
epidemiological and clinical significance. We denote the first as IHCM 1, for which we performed
a modified stepwise variable selection to determine the most important covariates that comprise
the intrinsic hazards for MI, stroke, HF and death.
We began with the full IHCM 1, comprised of the covariates deemed most important for
CVD. We included key baseline characteristics of the ALLHAT participants that are known to be
associated with CVD: age, race, sex, whether or not hypertension was treated at baseline, stage
1 or stage 2 hypertension as determined from baseline systolic and diastolic blood pressure,
smoking, previous MI or stroke, history of coronary revascularization (CABG), OASCVD, major ST
depression or T wave inversion, diabetes, left ventricular hypertrophy (LVH) by echocardiogram,
CHD, body mass index (BMI) and current aspirin use. For this paper, we used the previous
definition of stage 1 hypertension [systolic blood pressure (SBP) 140-160 mm Hg or diastolic
blood pressure (DBP) 90-100 mm Hg] and stage 2 hypertension [SBP > 160 mm Hg or DBP > 100
mm Hg] 10 to better reflect the ALLHAT in-trial period. Additionally, we added covariates that are
known CVD risk factors 1: baseline or incident atrial fibrillation (hereafter, atrial fibrillation) and
estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 as a marker of kidney disease.
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Lastly, we included the treatment arms amlodipine and lisinopril, with chlorthalidone serving as
the reference group for a total of 19 covariates for each intrinsic hazard (MI, stroke, HF and
death). Notably, we deliberately excluded HDL < 35 mg/dL, one of the ALLHAT baseline
characteristics reported in the literature

8,9

as a covariate for two main reasons. First and

foremost, a subset of the ALLHAT participants were enrolled during the trial into the Lipid-Lowing
Trial (ALLHAT-LLT) and were randomly assigned to receive pravastatin vs usual care and followed
for a mean of 4.8 years.11 This naturally introduces potential confounding as to the true effect of
dyslipidemia as measured by baseline HDL < 35 mg/dL on CVD events over the course of the trial.
Secondly, we ran a univariate IHCM with HDL < 35 mg/dL as the only covariate for all of the
intrinsic hazards with equivocal results: HDL < 35 mg/dL was not found to impart a statistically
significant hazard for MI or HF, and actually found to impart a statistically significant decrease in
hazard for stroke and death. These results are consistent with a potentially confounding effect
from the ALLHAT-LLT participants in the course of the ALLHAT study. Moreover, we ran a
univariate IHCM for each of the 19 covariates included in the full IHCM to determine its univariate
statistical significance as part of our model building and stepwise selection process (univariate
IHCM results not shown). Table 1 lists the details for the 19 covariates included in the full IHCM
1.
Starting with the full IHCM 1, we performed multiple rounds of backward selection. In
each round, we only retained the statistically significant covariates, i.e. the covariates which
imparted a statistically significant hazard to the total intrinsic hazards for MI, stroke, HF and
death, with one important constraint: we retained the treatment arms (amlodipine and lisinopril,
with chlorthalidone serving as the reference group) for every intrinsic hazard regardless of clinical
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significance throughout in order to adjust for treatment arm. In the first round of background
selection only the statistically significant covariates for each intrinsic hazard were retained, and
a reduced IHCM 1 model was fitted with these statistically significant covariates from the first
round. In this reduced IHCM 1 model (second round), any covariates that were no longer
statistically significant were discarded, and so on. The final reduced IHCM 1 contained only those
covariates that remained statistically significant in each round of backward selection, with the
noted exception of the treatment arms. We also removed a covariate even if it remained
statistically significant for a particular intrinsic hazard or set of intrinsic hazards, if it was not
statistically significant in the initial set of univariate analyses that we carried out for every
covariate in the full IHCM 1 model. And finally, ALLHAT’s population, given that every participant
had a diagnosis of hypertension and 1 or more additional CVD risk factors at baseline, posed a
unique challenge for variable selection; all statistically significant risk factors (covariates) could
not be included for stroke, HF and death as it would result in the reference group being too sparse
(the reference group being comprised of individuals without any of those risk factors). Therefore,
we had to remove additional covariates that remained statistically significant for stroke, HF and
death for optimal model stability to avoid the problems that arise with sparse data. Table 2
reports the covariates removed during multiple rounds of backward selection to yield the final
IHCM 1 model (henceforth, IHCM 1).
In order to study the possible interactions between treatment arms and selected risk
factors, we utilized IHCM 2, which contains as its covariates: the risk factor (binary or categorical),
amlodipine, lisinopril and the interaction terms [(risk factor) x (treatment arm)]. The selected risk
factors were sex, diabetes, race (black/nonblack), age (categorical, see Table 1), kidney disease,
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atrial fibrillation, hypertension treated at baseline and stage 1/stage 2 hypertension at baseline
(categorical, see Table 1). Of note, interactions for age, sex, race (black/nonblack) and diabetes
were previously studied in ALLHAT 8; we wanted to reexamine those interactions in a competing
risk framework for nonfatal CVD events and death with IHCM 2, and also examine additional risk
factors that play a crucial role in CVD: kidney disease, atrial fibrillation and hypertension. The
same set of covariates is included for each of the four intrinsic hazards (MI, stroke, HF and death)
for every interaction model with the recurrent hazards left as intercepts.
For the IRHCM, we began with IHCM 1 and added the full set of covariates (see Table 1)
for each recurrent hazard and performed multiple rounds of backward selection to determine
which covariates retained statistical significance for that recurrent hazard. Thus, we began with
the full covariates for 𝜷𝑴𝑴 (corresponding to covariate vector 𝑿𝑴𝑴𝒊 ) and determined its final set
of covariates via rounds of backward of selection. We then proceeded to perform variable
selection for 𝜷𝑴𝑺 in the same manner, retaining the final set of variables for the preceding 𝜷𝑴𝑴 ,
and so on, until variable selection for the last regression covariate coefficient vector, 𝜷𝑫𝑯 was
completed. Throughout this variable selection process, we assessed the goodness of fit for the
model up to that point using the approach that we described previously.6 Very briefly, we
predicted event-free survival at 1-year, 2-year, 3-year and 4-year increments for all individuals at
baseline, individuals that had 1 or more events, individuals that had 2 or more events, individuals
that had 3 or more events and individuals that had 4 or more events. Our dataset contained the
binary result of whether or not that individual had any event, nonfatal or fatal, within that time
frame; censored observations were handled in a manner identical to that detailed in our previous
work.6 We obtained the estimated area under the curve (AUC) and its standard error of the
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resulting receiver operating characteristic (ROC) curve for each time frame and number of events,
and this AUC was a measure of goodness of fit for the model.
For the IRHCM, the goodness of fit played a role in variable selection. If we found that the
statistically significant covariates that remained after backward selection for a particular
recurrent hazard resulted in lower AUC’s for one or more event histories (e.g. individuals with 3+
events, individuals with 4+ events, and so on) then we did not retain those covariates and opted
for an intercept term for that recurrent hazard. We report the backward selection process for
IRHCM in Table 3.
RESULTS
For IHCM 1 and IRHCM, a total of 3,062 observations (9.18%) were removed from the full
ALLHAT in-trial dataset (𝑁 = 33,357) due to missing values in the covariates, resulting in 30,295
observations for those analyses. For IHCM 2, 1,331 observations were removed for atrial
fibrillation due to missing covariates resulting in 32,026 observations; 1,460 observations were
removed for kidney disease due to missing covariates resulting in 31,897 observations; 1
observation was removed for hypertension treated at baseline due to a missing covariate
resulting in 33,356 observations. The parameter estimates and their 95% confidence intervals
(CI’s) for IHCM 1 are reported in Table 4. The intercept term for each intrinsic hazard regression
covariate coefficient vector (𝝁𝑴 , 𝝁𝑺 , 𝝁𝑯 and 𝝁𝑫 for MI, stroke, HF and death, respectively)
represents the reference group for all of the covariates in that intrinsic hazard. For MI, the
intercept term for 𝝁𝑴 corresponds to the reference group for all MI covariates, i.e. individuals
55-64 years of age, nondiabetic, no MI or stroke prior to the study, female, no prior CABG, no
history of OASCVD, normal kidney function (eGFR ≥ 60 ml/min/1.73m 2), no aspirin use,
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nonsmokers and in the chlorthalidone treatment arm. The MI intrinsic hazard parameter
intercept [0.0011 (0.0001, 0.0022)] represents the annual incidence of MI in these individuals.
The remaining parameters that comprise 𝝁𝑴 represent the additional, or excess, hazard
contributed by that covariate (which may be positive or negative) such that the covariate may
increase or decrease the absolute risk (in this case, annual incidence of MI). Neither amlodipine
nor lisinopril conferred statistically significant excess risk to MI as compared to chlorthalidone.
As an illustrative example, diabetes would impart an excess hazard of 0.0030, such that a diabetic
individual who was in the reference category for all other covariates would have an annual
incidence of MI: [0.0011 + 0.0030 = 0.0041]. For MI, age (the 65-79 year and 80+ year age groups),
diabetes, prior MI or stroke, male sex, previous CABG, history of OASCVD, kidney disease (eGFR
< 60 mL/min/1.73m2), aspirin use and smoking (past and current) are all statistically significant
risk factors that directly contribute to the annual incidence of MI. As a further example, a 66year-old male diabetic with kidney disease and history of OASCVD, who is a past smoker and
randomized to the chlorthalidone treatment arm would have an annual incidence of MI: [0.0011
+ 0.0035 + 0.0030 + 0.0038 + 0.0020 + 0.0019 + 0.0013 = 0.0166] and 95% CI (0.0144, 0.0188).
This corresponding Wald 95% CI is constructed using the standard error obtained from the
informative matrix which is itself obtained in the standard manner from the hessian matrix of the
log likelihood function detailed in our previous work

6

at the converged maximum likelihood

estimates.
The recurrent hazards (𝜷𝑴𝑴 , 𝜷𝑴𝑺 and 𝜷𝑴𝑯 ) are intercept terms and they are all positive
and statistically significant. Thus, MI, stroke and HF each imparts an additional (or excess) hazard
for a future MI. Similar to what we found in our previous work, 6 MI imparts the greatest hazard
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to its own recurrence [𝜷𝑴𝑴 ; 0.0543 (0.0473, 0.0613)], HF imparts the next highest hazard to
future MI [𝜷𝑴𝑯 ; 0.0123 (0.0070, 0.0175)]; followed by stroke [𝜷𝑴𝑺 ; 0.0092 (0.0035, 0.0149)]. The
intrinsic hazard of MI (as well as stroke, HF and death) can be calculated for any individual in the
dataset using a linear combination of their covariates and the parameter estimates provided in
Table 4; furthermore, the total hazard of any event (MI, stroke, HF or death) can be calculated as
the sum of that event’s intrinsic hazard, and any recurrent hazards accrued from prior nonfatal
events (MI, stroke and HF) that have occurred up to that point. To extend our example from the
previous paragraph, that very same 66-year-old male if he develops 1 MI, 0 strokes and 1 HF in
the course of the study up to the time point of interest, his updated annual incidence of MI would
be: [0.0166 + 0.0543 + 0 + 0.0123 = 0.0832] with 95% CI (0.0748, 0.0916).
The full results for MI, stroke, HF and death for IHCM 1 are provided in Table 4. We will
highlight the key results. Age, diabetes, previous MI or stroke, kidney disease and smoking are
the common risk factors for all of the intrinsic hazards (MI, stroke, HF and death). We first note
that age has a linear relationship with intrinsic stroke risk: from age 55 onward, the absolute risk
of stroke [0.0023 (0.0020, 0.0026)] increases linearly with every decade. We found in our
statistical analyses that the ordinal age variable (see Table 1 for details) provided the best fit (as
measured by the Akaike information criterion [AIC]) for univariate and multivariate IHCM models.
Furthermore, diabetes imparts a greater intrinsic risk to HF [0.0038 (0.0030, 0.0047)] than it does
to MI [0.0030 (0.0019, 0.0040)] and stroke [0.0030 (0.0022, 0.0038)], respectively. Similarly,
kidney disease imparts a greater intrinsic risk to HF [0.0037 (0.0024, 0.0050)] than it does to MI
[0.0020 (0.0005, 0.0035)] and stroke [0.0013 (0.0002, 0.0024)]. By contrast, prior MI or stroke as
a baseline covariate imparts similar risk to MI [0.0046 (0.0030, 0.0061)], stroke [0.0041 (0.0030,
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00.0052)] and HF [0.0042 (0.0030, 0.0053)]. Atrial fibrillation imparts more risk to HF [0.0230
(0.0174, 0.0287)] than it does to death [0.0097 (0.0038, 0.0156)] and stroke [0.0089 (0.0049,
0.0130)], but does not pose a statistically significant risk to MI. Stage 2 hypertension at baseline
imparts similar risk to stroke [0.0014 (0.0005, 0.0023)] and HF [0.0016 (0.0007, 0.0025)] but not
to MI or death. Diabetes imparts a higher risk to death [0.0085 (0.0070, 0.0101)] than it does to
the nonfatal events. Kidney disease [0.0145 (0.0119, 0.0172)] and current smoking [0.0141
(0.0120, 0.0163)] also confer a higher risk to death than they do to the nonfatal events. Similarly,
history of MI or stroke at baseline imparts approximately twice the risk to death [0.0088 (0.0067,
0.0109)] that it does to nonfatal events. For the treatment arms, there is a statistically significant
increase in risk of HF in amlodipine compared to chlorthalidone; lisinopril does not differ from
chlorthalidone for intrinsic risk of any of the four outcomes.
As is seen for MI, the recurrent hazards for stroke (𝜷𝑺𝑴 , 𝜷𝑺𝑺 and 𝜷𝑺𝑯 ), HF (𝜷𝑯𝑴 , 𝜷𝑯𝑺 and
𝜷𝑯𝑯 ) and death (𝜷𝑫𝑴 , 𝜷𝑫𝑺 and 𝜷𝑫𝑯 ) are all positive and statistically significant. Therefore, MI,
stroke and HF each imparts an additional hazard for its own recurrence, and that of one another
event’s occurrence or recurrence. Stroke imparts the greatest risk to its own recurrence [𝜷𝑺𝑺 ;
0.0226 (0.0160, 0.0291)] as does HF [𝜷𝑯𝑯 ; 0.1230 (0.1110, 0.1350)]. HF confers the highest risk
to death [𝜷𝑫𝑯 ; 0.0678 (0.0579, 0.0777)] followed by stroke [𝜷𝑫𝑺 ; 0.0419 (0.0315, 0.0523)] and
then MI [𝜷𝑫𝑴 ; 0.0086 (0.0036, 0.0137)].
We report the goodness of fit of IHCM 1 in Table 5. A key feature is the predictive role of
the covariates starting from baseline (0 events); at the 1-year mark, the AUC is statistically
significant and reasonably predictive [0.67 [0.65, 0.68]), which holds steady at 2 years [0.67 (0.66,
0.68)] and rises slightly at the 3-year mark [0.68 (0.67, 0.69)], remaining there at 4 years [0.68
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(0.68, 0.69)]. However, the AUC drops for individuals with 1+ events at 1 year [0.61 (0.59, 0.63)],
rising to [0.63 (0.61, 0.65)] at the 2-year mark, and remaining there for 3 years [0.63 (0.61, 0.65)]
and 4 years [0.63 (0.61, 0.65)], respectively. The AUC drops further for 2+ events at 1 year [0.57
(0.54, 0.61)] before rising slightly at the 2-year mark [0.58 (0.54, 0.62)], and continuing to rise at
the 3-year [0.59 (0.55, 0.64)] and 4-year mark [0.62 (0.57, 0.67)], respectively. The AUC starts to
climb back up for 3+ events at year 1 [0.60 (0.54, 0.66)], rising steadily up to year 3 [0.67 (0.59,
0.75)] before dipping slightly at year 4 [0.65 (0.55, 0.76)]. The AUC’s are the highest overall for
4+ events, beginning at year 1 [0.67 (0.58, 0.76)], with a steady rise at years 2 and 3 [0.68 (0.57,
0.78) and 0.70 (0.57, 0.82), respectively] and leveling off at year 4 [0.70 (0.56, 0.84)].
IHCM 2 examines interactions between treatment groups and the 8 selected risk factors
described in the previous section. In Table 6, we report the results of the 3 risk factors that had
one or more statistically significant interactions with treatment arms amlodipine and/or
lisinopril, compared to chlorthalidone. The interaction of diabetes and amlodipine was positive
and statistically significant for HF, which suggests that diabetes conferred a greater risk of
developing HF in the amlodipine arm when compared to the risk of HF conferred by diabetes in
the chlorthalidone arm. Next, the interaction of black race and lisinopril was positive and
statistically significant for stroke. This suggests that blacks were at higher risk of stroke in the
lisinopril group, compared to blacks’ risk of stroke in the chlorthalidone group. Finally, the
interaction of atrial fibrillation and amlodipine, and the interaction of atrial fibrillation and
lisinopril, are both negative and statistically significant for death compared to chlorthalidone.
This suggests that the risk of death conferred by atrial fibrillation is lower in both amlodipine
compared to chlorthalidone and in lisinopril compared to chlorthalidone. The remaining 5 risk
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factors, age, sex, kidney disease, hypertension treated at baseline and stage 1/stage 2
hypertension at baseline did not have statistically significant interactions with the treatment
arms for MI, stroke, HF or death.
We now turn to the IRHCM. The IRHCM retains the intrinsic hazard covariates of IHCM 1
(Table 4) and the intrinsic hazard parameter values of IRHCM are similar or identical to that of
IHCM 1, as expected. The recurrent hazard covariates of IRHCM, having undergone variable
selection (modified backward selection as described in the methods section), retained several
such covariates in the final IRHCM (Table 7). For 𝜷𝑴𝑴 , which denotes the risk that MI imparts to
its own recurrence, male sex imparts additional risk [0.0218 (0.0079, 0.0357)] to recurrent MI as
compared to female sex; similarly, kidney disease imparts risk [0.0246 (0.0061, 0.0431)] to
recurrent MI as compared to normal kidney function. For 𝜷𝑴𝑯 , which denotes the risk that HF
imparts to future MI, diabetes imparts additional risk [0.0136 (0.0029, 0.0242)] as compared to
nondiabetic. For 𝜷𝑯𝑴 , which denotes the risk that MI imparts to future HF occurrence, age (both
the 65-79 years age group and the over 80+ years age group) imparts risk of [0.0182 (0.0056,
0.0308)] and [0.0627 (0.0232, 0.1022)], respectively. Diabetes [0.0431 (0.0280, 0.0582)], history
of OASCVD [0.0183 (0.0023, 0.0342)], and kidney disease [0.0275 (0.0081, 0.0470)] also impart
risk to future HF occurrence in those with previous MI. Moreover, the amlodipine treatment arm
imparts additional risk [0.0160 (0.0005, 0.0314)] compared to chlorthalidone to future HF in
those with previous MI. For 𝜷𝑯𝑯 , which denotes the risk that HF imparts to its own recurrence,
lisinopril lowers risk [-0.0302 (-0.0553, -0.0051)] as compared to chlorthalidone for HF
recurrence. For 𝜷𝑫𝑴 , which denotes the risk that MI imparts to death, age (those 65 years and
above) imparts risk [0.0176 (0.0085, 0.0268)]. This holds true for both the remaining two
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recurrent hazards for death; for 𝜷𝑫𝑺 , age (ordinal, with the 55-64 years age group serving as the
reference group) for every decade-increase starting at age 65 imparts risk to death from previous
stroke [0.0228 (0.0166, 0.0290)]. For 𝜷𝑫𝑯 , age 65 years and above imparts risk of death from
prior HF.
The goodness of fit of IRHCM is detailed in Table 8. The predictive role of the covariates
starting at baseline (0 events) is retained and identical to that of IHCM. The AUC drops for 1+
events at 1 year [0.62 (0.60, 0.64)], rising to [0.64 (0.62, 0.66)] at the 2-year mark, and remaining
there at 3 years [0.64 (0.62, 0.66)] and rising again at the 4-year point [0.66 (0.64, 0.68)]. The AUC
drops further for 2+ events at 1 year [0.59 (0.55, 0.62)] before rising slightly at the 2-year mark
[0.60 (0.57, 0.64)], and continuing to rise at the 3-year [0.62 (0.58, 0.66)] and 4-year mark [0.66
(0.61, 0.70)]. The AUC starts remains lower for 3+ events at year 1 [0.59 (0.53, 0.65)], rising
steadily up to year 3 [0.65 (0.57, 0.73)] before dipping slightly at year 4 [0.64 (0.53, 0.75)]. The
AUC’s are highest overall for 4+ events, beginning at year 1 [0.63 (0.54, 0.72)], with a steady rise
at years 2 and 3 [0.65 (0.54, 0.76) and 0.73 (0.60, 0.85), respectively] and jumping to [0.80 (0.67,
0.94)] at year 4. Overall, the IRHCM AUC’s are improved over that of the IHCM, specifically for
the 1+, 2+ and 4+ events.
DISCUSSION
In this paper, we extend our previous work significantly to include important covariates
for both the intrinsic hazards for MI, stroke, HF and death [i.e. the so-called major adverse
cardiovascular events (MACE)] in IHCM 1, and to include important covariates for both the
intrinsic and recurrent hazards in IRHCM. Recently, there has been a great deal of renewed and
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significant interest in MACE and our work provides additional, critical insights in this important
area.12
The majority of survival analysis models, including the Cox proportional hazards model
13,14

provide hazard ratios/relative risks of risk factors, leaving the baseline hazards, or absolute

risks, unspecified. Our model is unique in that it directly provides the absolute risk, in the form
of risk in excess to that of a reference group that is easily transformed to the absolute risk for an
individual with a certain clinical profile and event history, for each of the MACE outcomes in this
model (MI, stroke, HF and death), accounting for the competing nature of these cardiovascular
(CV) events. In so doing, our model clearly delineates the risk factors for each particular CV event,
allowing that event to have its own set of risk factors, and further delineates the risk factors for
CVD recurrence. IHCM 1 showed that age, diabetes, a history of MI or stroke, kidney disease and
smoking are common risk factors for all four intrinsic hazards. This is consistent with the vast
clinical and epidemiological literature and known pathophysiology of CVD.1,3-5,7,12,15,16 It is worth
noting that three of these risk factors are included in the original Framingham risk score, the
other two being dyslipidemia and hypertension.17 This allows us to segue into risk factors for
specific CV outcomes. ALLHAT’s population was comprised of hypertensive individuals aged 55
years or above, with at least one additional CV risk factor. Because each ALLHAT participant was
randomized to one three antihypertensive treatment arms, their blood pressure (BP) was
managed during the trial. This likely blunted the effect of hypertension in CVD occurrence and
recurrence in the course of the trial in comparison to that of a purely observational study,
particularly as there were modest differences in mean blood pressure of participants between
the three treatment arms at subsequent yearly follow-up visits (given the large sample size of
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ALLHAT, even the small mean BP differences between treatment arms were statistically
significant). IHCM 1 showed baseline hypertension to be a significant risk factor for stroke and
HF, but not MI or death which suggests that stroke and HF are more sensitive to current or past
hypertension than are MI and death. Atrial fibrillation was a significant risk factor for stroke, HF
and death, but not for MI when adjusted for other risk factors. IHCM 1 also showed that atrial
fibrillation conferred its greatest risk to HF and conferred comparatively lower risk to death and
stroke. In a similar vein, returning to the risk factors common to all four outcomes, diabetes
imparts greater risk to HF than it does to MI or stroke, but imparts its most risk overall to death.
There has been a great deal of recent literature and studies focusing on the unique relationship
between diabetes and HF, i.e. diabetes increases the risk of HF and worsens HF’s disease course
and prognosis.12,15,16,18,19 Studies have also suggested that diabetes may confer more risk to HF
than it does to (nonfatal) MI or stroke, as reflected in our analyses.12,18 Kidney disease, in a similar
pattern confers more risk to HF than it does to MI or stroke, and its highest risk to death. These
patterns of risk factors and their clearly demarcated conferral of risk to specific CVD outcomes –
conferring greater risk to some events, less risk to others, and in some cases, no significant risk
to an event or events – yields valuable insight into the nature of CVD which in turn guides
therapeutic management tailed to an individual’s clinical profile. If a patient has certain risk
factors, it is imperative to identify which CVD event(s) they are at highest risk for, and to select a
treatment regimen that addresses that. For example, in an elderly male (80+ years of age) with
diabetes, kidney disease and atrial fibrillation, the most likely nonfatal event would be HF, and
they are of course at high risk of death as well; if this individual were to develop HF, their risk of
dying at that point or soon thereafter would be high. Since our models showed that amlodipine
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conferred risk of HF compared to chlorthalidone, and lisinopril lowered risk of recurrent HF
conferred by antecedent HF, this individual would likely benefit from an ACE inhibitor as part of
their drug regimen (barring other contraindications) whereas amlodipine should be avoided.
Another important aspect of CVD is CVD-related death. Our model includes all-causemortality (death) as one of the four competing events, death being the terminating event that is
dependent on, or impacted by, one or more of the other three events (MI, stroke and HF)
occurring beforehand. IHCM 1 yields the risk factors for death, which is particularly valuable
because it delineates the separate risk that a particular risk factor (e.g. diabetes, kidney disease)
confers to death, aside from the risk that that factor poses to CV events which in turn also
increase the risk of death. In this manner, we can quantify the additional risk that diabetes, or
atrial fibrillation or some other risk factor directly confers to death, and this risk is separate from
that already posed by a prior CV event such as MI, stroke or HF. There are individuals who die
from long-term complications of a chronic disease like diabetes or kidney disease without ever
developing MI, stroke or HF. Our model provides both types of risks – the risk directly posed by
a risk factor or disease process, and the risk posed by a prior CV event, which in turn is likely
associated with the risk factor(s). This provides valuable risk quantification and stratification in
both types of patients – those with risk factors and no prior CV events, and those with risk factors
and prior CV events.
We will briefly mention the potential ramifications of the statistically significant
interactions between treatment arms and risk factors shown by IHCM 2. First, the positive
interaction between black race and lisinopril for stroke risk has been reported previously, 8,9 and
may partially reflect the diminished effectiveness of ACE inhibitors in blacks; their hypertension
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is not as well controlled on lisinopril, resulting in increased stroke risk compared to
chlorthalidone. The positive interaction of diabetes and amlodipine for HF risk may be partially
reflective of the strong association between diabetes and HF; since the amlodipine arm contained
a higher incidence of HF, this interaction may be reflective of a synergistic effect of diabetes and
amlodipine in HF risk. Finally, the significant interactions between atrial fibrillation and both
amlodipine and lisinopril such that both arms show a decreased risk of death compared to
chlorthalidone, may suggest a protective role of amlodipine and lisinopril, respectively,
compared to chlorthalidone in preventing death in those with atrial fibrillation in the long-term.
Amlodipine was shown in a previous ALLHAT paper to lower the risk of death from atrial
fibrillation compared to chlorthalidone.20
We now turn to our models’ predictive capabilities. IHCM 1 showed the significant role of
risk factors in individuals with 0 events (i.e. study baseline), with reasonably good predictive
capabilities at the 1, 2, 3 and 4-year time points. The predictive ability of IHCM 1 drops for 1+
events, 2+ events and 3+ events, with the 2+ events faring the worst at the 1-year time point.
Prediction improves with by the 3 to 4-year time points, which suggests that the ability of events
history to predictive future event occurrence or recurrence improves with increased time
elapsed. IHCM 1 performs best in individuals with 4+ events, reaching AUC of 0.70 by the 3-year
time point, which is quite good in this context. IRHCM performs better than IHCM for the 1+, 2+
and 4+ events, and comparatively for the 3+ events, which suggests that recurrent hazards
covariates play a role in prediction, particularly age (risk of death conferred by prior MI, stroke
and HF; risk of HF conferred by prior MI), diabetes (risk of MI conferred by prior HF; risk of HF
conferred by prior MI), and kidney disease (risk of MI conferred by prior MI; risk of HF conferred

66

by prior MI) among others. IRHCM performs particularly well for individuals with 4+ events,
reaching AUC of 0.73 at the 3-year mark, and climbing all the way up to 0.80 at the 4-year mark.
For 1+ and 2+ events, IRHCM nearly catches up to the baseline/0 events individuals, reaching
AUC of 0.66 by the 4-year mark. Both the IHCM 1 and the IRHCM have significant potential for
utility as a clinical risk score or decision rule that utilizes both risk factors and event history to
assist prediction of future events.
The overall pattern of both IHCM and IRHCM to perform best for individuals at baseline
(0 events) and individuals with 4+ events suggest several things. First, the risk factors tailored to
each event type play a dominant role in prediction. Second, individuals with 4+ events tend to
have 1 or more HF events in their history. Since HF tends to be a late event, in the sense that it
tends to have antecedent CV event(s) such as MI, and HF itself is a strong risk factor for future
HF, this heightened predictive capability of both IHCM and IRHCM is likely reflective of that.
We now acknowledge a couple of limitations which we view as important future
directions and extensions of our work. First, the decrease in AUC’s for the 1+, 2+ and 3+ events
particularly at the earlier time points can be partially explained by the fact that the increased risk
posed by an event may be ameliorated by intervention or management of risk factors at that
time, going forward. Such interventions can be addressed by time dependent covariates,
whereas we utilized fixed covariates for all of our analyses. Our reasons for doing so are two-fold:
first, as in any longitudinal study, there are missing covariates both at baseline and at subsequent
follow up time points. We already removed observations with missing baseline covariates for our
models, which was fortunately a relatively small proportion (< 10%) and unlikely to be of
consequence in our analyses. However, employing time dependent covariates from follow up
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time points would ensure removal of additional individuals with missing covariates, which would
likely compromise our analyses, particularly given the relatively small total number of recurrent
CVD events in the ALLHAT in-trial dataset. The handling of missing covariates, particularly in
longitudinal studies, is a very important area of inquiry, and would be an important extension of
our work, allowing for and potentially combining with, time-dependent analyses. Second, we
wanted our already complex models to handle fixed covariates first in order to determine how
well the models performed before attempting to handle time-dependent covariates, which is
inherently more complex.
A second limitation was our inability to use biomarkers, in part because ALLHAT was a
large, simple trial that did not utilize biomarkers and also because biomarkers are much more
ubiquitous today, with many of them having been discovered or repurposed in the last decade,
after ALLHAT’s in-trial period ended. Biomarkers such as NT-proBNP

21-23

which have been

extensively validated for HF occurrence and recurrence and more recently linked to stroke
occurrence and recurrence

22,23

would be a natural covariate to add to our models when the

models are applied to longitudinal studies that measure them. Moreover, the addition of
biomarkers as covariates would likely improve performance of our models for the individuals
with 1+, 2+, 3+ and 4+ events. Finally, we also applied our models to the same dataset for both
parameter estimation and to assess predictive capabilities, which did not allow us to validate our
model on data it has never seen. This last issue can be addressed by a supervised learning
approach, which is the subject of a future work.
In closing, we anticipate that our models will play a significant role in the development of
clinical CVD risk scores and related decision rules/algorithms that incorporate both risk factors
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and event history, with the exciting addition of biomarkers both old and new, that will aid every
physician in the optimal management and treatment of CVD and related disease, including risk
factors that are quite often chronic diseases with devastating sequelae of their own. Given the
enormous global CVD burden mentioned in the beginning of this paper, such a tool (or tools)
cannot arrive soon enough.
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Table 1. Full IHCM 1 covariates
Variable type

Reference Group

Additional categories or values
Age 65-79;
Age ≥ 80
0 = Age 55-64
1 = Age 65-74
2 = Age 75-84
3 = Age ≥ 85
Yes
Yes
Male
Black
Yes
Yes

Age, years

Categorical

Age 55-64

Age*

Ordinal

--

Diabetes (at baseline)
Previous MI or stroke
Sex
Black
Previous CABG
Hypertension treated at
baseline
Hypertension (at
baseline, based on
average of two BP
readings, mmHg)

Binary
Binary
Binary
Binary
Binary
Binary

No
No
Female
Nonblack
No
No

Categorical

SBP < 140 and DBP
< 90

History of OASCVD
Atrial fibrillation
(baseline or incident,
detected by ECG at
baseline or follow-up
visit)
Kidney disease (at
baseline)
Aspirin use (at baseline)
Smoking history

Binary
Binary

No
No

Binary
Binary
Categorical

GFR ≥ 60
mL/min/1.73m2
No
Nonsmoker

LVH by echocardiogram
(at baseline)
Obesity (at baseline)
CHD (at baseline)
Major ST depression or
T-wave inversion on ECG
(at baseline)
Treatment arm

Binary

No

Yes
Past smoker;
current smoker
Yes

Binary
Binary
Binary

BMI < 30 kg/m2
No
No

BMI ≥ 30 kg/m2
Yes
Yes

Categorical

Chlorthalidone

Stage 1 hypertension
(140 ≤ SBP < 160 and 90 < DBP <
100);
Stage 2 hypertension
(SBP ≥ 160 or DBP ≥ 100)
Yes
Yes

GFR < 60 mL/min/1.73m2

Amlodipine;
Lisinopril
Abbreviations: BP, blood pressure; CABG, coronary artery bypass graft; CHD, coronary heart
disease; DBP, diastolic blood pressure; ECG, electrocardiogram; GFR, glomerular filtration rate;
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MI, myocardial infarction; OASCVD, other atherosclerotic cardiovascular disease; SBP, systolic
blood pressure.
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Table 2. Modified backward selection for IHCM 1 covariates
MI
Stroke
⸶
Age 65-79
Age
Age ≥ 80
Diabetes
Diabetes
Previous MI or stroke
Previous MI or stroke
Sex
Sex
Black
Black
Stage 1 HTN
FULL IHCM 1:
Previous CABG
Stage 2 HTN
STATISTICALLY
History of OASCVD
History of OASCVD
SIGNIFICANT
Kidney disease
Atrial fibrillation
COVARIATES
Aspirin use
Kidney disease
Past smoker
Current smoker
Current smoker
CHD
*
ST depression
Amlodipine‖

BS 1

BS 2
BS 3
BS 4
FINAL IHCM 1

REMOVE:
Black
ST depression
---Age 65-79
Age ≥ 80
Diabetes
Previous MI or stroke
Sex
Previous CABG
History of OASCVD

HF

REMOVE: CHD

Age 65-79
Age ≥ 80
Diabetes
Previous MI or stroke
Black
Previous CABG
Stage 2 HTN
History of OASCVD
Atrial fibrillation
Kidney disease
Past smoker
Current smoker
LVH
Obesity
Amlodipine‖
Lisinopril‖
REMOVE: Obesityǂ

REMOVE: OASCVDǂ
REMOVE: Stage 1 HTNǂ
REMOVE: Blackǂ
Age⸶
Diabetes
Previous MI or stroke
Sex
Stage 2 HTN
Atrial fibrillation
Kidney disease

REMOVE: Past smokerǂ
REMOVE: Blackǂ
REMOVE: Age 65-79ǂ
Age ≥ 80
Diabetes
Previous MI or stroke
Previous CABG
Stage 2 HTN
History of OASCVD
Atrial fibrillation
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Death
Age 65-79
Age ≥ 80
Diabetes
Previous MI or stroke
Sex
Black
History of OASCVD
Atrial fibrillation
Kidney disease
Aspirin use
Past smoker
Current smoker
LVH
Obesity

REMOVE: LVH

REMOVE: Aspirin use§
REMOVE: Obesityǂ
-Age 65-79
Age ≥ 80
Diabetes
Previous MI or stroke
Sex
Black
History of OASCVD

Kidney disease
Current smoker
Kidney disease
Atrial fibrillation
Aspirin use
Amlodipine
Current smoker
Kidney disease
Past smoker
Lisinopril
LVH
Past smoker
Current smoker
Amlodipine
Current smoker
Amlodipine
Lisinopril
Amlodipine
Lisinopril
Lisinopril
Abbreviations: BS, backward selection; CABG, coronary artery bypass graft; CHD, coronary heart disease; DBP, diastolic blood pressure;
HTN, hypertension; LVH, left ventricular hypertrophy; MI, myocardial infarction; OASCVD, other atherosclerotic cardiovascular
disease; SBP, systolic blood pressure.
*Refers to major ST depression or T-wave inversion on electrocardiogram (ECG).
⸶For stroke, the age variable is ordinal as detailed in Table 1.
ǂRemoved as a covariate to stabilize the model as the regression covariate vector could not handle all statistically significant covariates.
§Aspirin use was found to be statistically not significant for death on the univariate IHCM, so it was removed in the second round of
backward selection.
‖Treatment arm found to be a statistically significant covariate; treatments arms were retained as covariates for the intrinsic hazards
regardless of statistical significance.
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Table 3. Modified backward selection for IRHCM recurrent hazards covariates
MM
MS
MH
Sex
Atrial fibrillation Diabetes
STATISTICALLY
SIGNIFICANT
COVARIATES AT
THE START OF
BACKWARD
SELECTION (BS)
BS 1

--

REMOVE:
Atrial fibrillation

--

BS 2

--

--

--

FINAL
STATISTICALLY
SIGNIFICANT
COVARIATES

Sex
Kidney disease*

Intercept

Diabetes

STATISTICALLY
SIGNIFICANT
COVARIATES AT
THE START OF
BACKWARD
SELECTION (BS)

HM
Age 65-79
Age ≥ 80
Diabetes
Previous MI or stroke
History of OASCVD
Kidney disease

HS

HH

Sex
Previous CABG
Stage 2 HTN
Atrial fibrillation
Kidney disease
Aspirin use

Black
History of OASCVD
Lisinopril
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SM
Previous MI or
stroke
Sex
Black
History of OASCVD
Atrial fibrillation
Aspirin use
Lisinopril
REMOVE:
History of OASCVD
Atrial fibrillation
REMOVE:
Previous MI or
stroke
Sex
Black
Aspirin use
Lisinopril
Intercept

SS
Previous CABG
Stage 2 HTN
Kidney disease

SH
Amlodipine

REMOVE:
Previous CABG

REMOVE:
Amlodipine

--

--

Stage 2 HTN
Kidney disease

Intercept

DM
Age 65-79

DS
Age ≥ 80
Diabetes
Black
Previous CABG

DH
Age 65-79
Sex
Stage 2 HTN
Atrial fibrillation

Amlodipine
BS 1

REMOVE:
Previous MI or stroke

BS 2

--

BS 3

--

Past smoker
Amlodipine
REMOVE:
Kidney disease
Past smoker
Amlodipine
REMOVE:
Sex
Aspirin use
REMOVE:
Previous CABG
Stage 2 HTN
Atrial fibrillation

--

--

REMOVE:
Diabetes
Black

REMOVE:
Sex

--

--

REMOVE:
Previous CABG

--

--

--

--

--

Age 65-79
Black
Ageǂ
Age ≥ 65⸶
Age ≥ 65⸶
Age ≥ 80
History of OASCVD
Stage 2 HTN
Diabetes
Lisinopril
Atrial fibrillation
History of OASCVD
Kidney disease
Amlodipine
Abbreviations: BS, backward selection; CABG, coronary artery bypass graft; HTN, hypertension; LVH, left ventricular hypertrophy; MI,
myocardial infarction; OASCVD, other atherosclerotic cardiovascular disease.
*Kidney disease was found to be statistically significant when the full set of MM covariates was rerun, after diabetes was retained as
a covariate for MH; retaining the full set of MM covariates improved the model goodness of fit (reflected by higher AUC’s) in spite of
most of the covariates being statistically not significant, so it was rerun after backward selection was completed for MM, MS and MH.
⸶Age 65-79 covariate was converted to the binary covariate Age ≥ 65 in scenarios in which the Age 65-79 covariate was retained but
Age ≥ 80 was dropped during backward selection.
ǂAge as an ordinal variable (refer to Table 1 for details) was found to yield an improved goodness of fit (reflected by higher AUC’s) as
compared to Age ≥ 80, so ordinal Age was retained for the final IRHCM.

FINAL
STATISTICALLY
SIGNIFICANT
COVARIATES
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Table 4. IHCM 1

MI

Stroke

HF

Baseline (excess) hazard/absolute risk*
Estimate (95% CI)

Parameter
𝝁𝑴
Intercept
Age
65-79
≥ 80
Diabetes
Previous MI or stroke
Sex
Previous CABG
History of OASCVD
Kidney disease
Aspirin use
Smoking
Past
Current
Amlodipine
Lisinopril
𝜷𝑴𝑴
𝜷𝑴𝑺
𝜷𝑴𝑯
𝝁𝑺
Intercept
Age*
Diabetes
Previous MI or stroke
Sex
Hypertension (Stage 2)
Atrial fibrillation
Kidney disease
Smoking (Current)
Amlodipine
Lisinopril
𝜷𝑺𝑴
𝜷𝑺𝑺
𝜷𝑺𝑯
𝝁𝑯
Intercept
Age (≥ 80)
Diabetes
Previous MI or stroke

0.0011 (0.0001, 0.0022)
0.0035 (0.0025, 0.0045)
0.0064 (0.0037, 0.0091)
0.0030 (0.0019, 0.0040)
0.0046 (0.0030, 0.0061)
0.0038 (0.0027, 0.0048)
0.0089 (0.0066, 0.0112)
0.0019 (0.0007, 0.0032)
0.0020 (0.0005, 0.0035)
0.0018 (0.0006, 0.0029)
0.0013 (0.0002, 0.0023)
0.0032 (0.0019, 0.0045)
-0.0003 (-0.0014, 0.0008)
-0.0001 (-0.0012, 0.0009)
0.0543 (0.0473, 0.0613)
0.0092 (0.0035, 0.0149)
0.0123 (0.0070, 0.0175)
0.0007 (0.0001, 0.0012)
0.0023 (0.0020, 0.0026)
0.0030 (0.0022, 0.0038)
0.0041 (0.0030, 0.0052)
0.0013 (0.0007, 0.0019)
0.0014 (0.0005, 0.0023)
0.0089 (0.0049, 0.0130)
0.0013 (0.0002, 0.0024)
0.0024 (0.0014, 0.0033)
-0.0004 (-0.0010, 0.0002)
0.0007 (-0.0002, 0.0015)
0.0031 (0.0006, 0.0056)
0.0226 (0.0160, 0.0291)
0.0032 (0.0002, 0.0063)
0.0006 (0.0002, 0.0010)
0.0065 (0.0038, 0.0092)
0.0038 (0.0030, 0.0047)
0.0042 (0.0030, 0.0053)
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Previous CABG
0.0039 (0.0023, 0.0054)
Hypertension (Stage 2)
0.0016 (0.0007, 0.0025)
History of OASCVD
0.0016 (0.0007, 0.0025)
Atrial fibrillation
0.0230 (0.0174, 0.0287)
Kidney disease
0.0037 (0.0024, 0.0050)
Smoking (Current)
0.0008 (0.0001, 0.0015)
LVH by echocardiogram
0.0023 (0.0005, 0.0040)
Amlodipine
0.0020 (0.0011, 0.0029)
Lisinopril
0.0005 (-0.0002, 0.0011)
𝜷𝑯𝑴
0.0558 (0.0487, 0.0630)
𝜷𝑯𝑺
0.0114 (0.0057, 0.0171)
𝜷𝑯𝑯
0.1230 (0.1110, 0.1350)
Death
𝝁𝑫
Intercept
0.0008 (-0.0001, 0.0017)
Age
65-79
0.0109 (0.0094, 0.0125)
≥ 80
0.0564 (0.0503, 0.0625)
Diabetes
0.0085 (0.0070, 0.0101)
Previous MI or stroke
0.0088 (0.0067, 0.0109)
Sex
0.0059 (0.0044, 0.0074)
Black
0.0029 (0.0016, 0.0043)
History of OASCVD
00027 (0.0011, 0.0043)
Atrial fibrillation
0.0097 (0.0038, 0.0156)
Kidney disease
0.0145 (0.0119, 0.0172)
Smoking
Past
0.0032 (0.0018, 0.0046)
Current
0.0141 (0.0120, 0.0163)
Amlodipine
0.0003 (-0.0009, 0.0015)
Lisinopril
-0.0002 (-0.0014, 0.0010)
𝜷𝑫𝑴
0.0086 (0.0036, 0.0137)
𝜷𝑫𝑺
0.0419 (0.0315, 0.0523)
𝜷𝑫𝑯
0.0678 (0.0579, 0.0777)
Abbreviations: CABG, coronary artery bypass graft; LVH, left ventricular hypertrophy; MI,
myocardial infarction; OASCVD, other atherosclerotic cardiovascular disease.
*Excess hazard/absolute risk is the additional hazard/risk imparted by a risk factor compared to
its reference group.

79

Table 5. Area under the curve for the IHCM 1.
Year
1
2
3
4

0 events
N=30,295
0.67
(0.65, 0.68)
0.67
(0.66, 0.68)
0.68
(0.67, 0.69)
0.68
(0.68, 0.69)

1+ events
N=3,358
0.61
(0.59, 0.63)
0.63
(0.61, 0.65)
0.63
(0.61, 0.65)
0.63
(0.61, 0.65)

2+ events
N=940
0.57
(0.54, 0.61)
0.58
(0.54, 0.62)
0.59
(0.55, 0.64)
0.62
(0.57, 0.67)

80

3+ events
N=370
0.60
(0.54, 0.66)
0.64
(0.58, 0.70)
0.67
(0.59, 0.75)
0.65
(0.55, 0.76)

4+ events
N=145
0.67
(0.58, 0.76)
0.68
(0.57, 0.78)
0.70
(0.57, 0.82)
0.70
(0.56, 0.84)

Table 6. IHCM 2: Interactions
DIABETES (N=33,357)

MI

Stroke

HF

Death

Baseline (excess) hazard/absolute risk*
Estimate (95% CI)

Parameter
𝝁𝑴
Intercept
Diabetes
Amlodipine
Lisinopril
Diabetes x Amlodipine
Diabetes x Lisinopril
𝜷𝑴𝑴
𝜷𝑴𝑺
𝜷𝑴𝑯
𝝁𝑺
Intercept
Diabetes
Amlodipine
Lisinopril
Diabetes x Amlodipine
Diabetes x Lisinopril
𝜷𝑺𝑴
𝜷𝑺𝑺
𝜷𝑺𝑯
𝝁𝑯
Intercept
Diabetes
Amlodipine
Lisinopril
Diabetes x Amlodipine
Diabetes x Lisinopril
𝜷𝑯𝑴
𝜷𝑯𝑺
𝜷𝑯𝑯
𝝁𝑫
Intercept
Diabetes
Amlodipine
Lisinopril
Diabetes x Amlodipine
Diabetes x Lisinopril
𝜷𝑫𝑴
𝜷𝑫𝑺

0.0102 (0.0093, 0.0111)
0.0021 (0.0004, 0.0037)
0.0002 (-0.0013, 0.0017)
-0.0008 (-0.0023, 0.0006)
-0.0018 (-0.0044, 0.0008)
0.0003 (-0.0024, 0.0029)
0.0559 (0.0492, 0.0626)
0.0125 (0.0069, 0.0181)
0.0152 (0.0100, 0.0203)
0.0051 (0.0044, 0.0057)
0.0031 (0.0019, 00044)
-0.0001 (-0.0011, 0.0010)
0.0011 (<0.0001ǂ, 0.0023)
-0.0011 (-0.0031, 0.0009)
-0.0006 (-0.0028, 0.0016)
0.0036 (0.0012, 0.0061)
0.0246 (0.0184, 0.0309)
0.0050 (0.0019, 0.0081)
0.0046 (0.0040, 0.0052)
0.0027 (0.0015, 0.0040)
0.0018 (0.0006, 0.0029)
0.0005 (-0.0005, 0.0016)
0.0031 (0.0007, 0.0054)⸶
0.0009 (-0.0013, 0.0030)
0.0578 (0.0508, 0.0648)
0.0146 (0.0091, 0.0201)
0.1265 (0.1151, 0.1379)
0.0253 (0.0239, 0.0268)
0.0073 (0.0046, 0.0099)
-0.0014 (-0.0037, 0.0010)
-0.0006 (-0.0029, 0.0018)
-0.0008 (-0.0050, 0.0034)
-0.0005 (-0.0048, 0.0038)
0.0145 (0.0091, 0.0198)
0.0527 (0.0425, 0.0629)
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𝜷𝑫𝑯

0.0725 (0.0629, 0.0821)
RACE (N=33,357)

MI

Stroke

HF

Death

Baseline (excess) hazard/absolute risk*
Estimate (95% CI)

Parameter
𝝁𝑴
Intercept
Black
Amlodipine
Lisinopril
Black x Amlodipine
Black x Lisinopril
𝜷𝑴𝑴
𝜷𝑴𝑺
𝜷𝑴𝑯
𝝁𝑺
Intercept
Black
Amlodipine
Lisinopril
Black x Amlodipine
Black x Lisinopril
𝜷𝑺𝑴
𝜷𝑺𝑺
𝜷𝑺𝑯
𝝁𝑯
Intercept
Black
Amlodipine
Lisinopril
Black x Amlodipine
Black x Lisinopril
𝜷𝑯𝑴
𝜷𝑯𝑺
𝜷𝑯𝑯
𝝁𝑫
Intercept
Black
Amlodipine
Lisinopril
Black x Amlodipine
Black x Lisinopril
𝜷𝑫𝑴
𝜷𝑫𝑺

0.0125 (0.0115, 0.0135)
-0.0042 (-0.0057, -0.0027)
-0.0006 (-0.0022, 0.0011)
-0.0014 (-0.0030, 0.0002)
0.0005 (-0.0020, 0.0029)
0.0019 (-0.0006, 0.0043)
0.0555 (0.0488, 0.0622)
0.0126 (0.0070, 0.0182)
0.0156 (0.0105, 0.0208)
0.0059 (0.0052, 0.0066)
0.0009 (-0.0003, 0.0021)
-0.0004 (-0.0015, 0.0008)
<0.0001ǂ (-0.0012, 0.0011)
-0.0003 (-0.0023, 0.0016)
0.0026 (0.0004, 0.0047)⸶
0.0036 (0.0012, 0.0061)
0.0249 (0.0186, 0.0312)
0.0051 (0.0020, 0.0083)
0.0054 (0.0048, 0.0061)
0.0003 (-0.0008, 0.0015)
0.0033 (0.0020, 0.0046)
0.0006 (-0.0005, 0.0018)
-0.0010 (-0.0031, 0.0012)
0.0005 (-0.0015, 0.0025)
0.0583 (0.0513, 0.0653)
0.0152 (0.0096, 0.0207)
0.1269 (0.1154, 0.1383)
0.0271 (0.0256, 0.0286)
0.0022 (-0.0003, 0.0048)
-0.0020 (-0.0044, 0.0004)
-0.0017 (-0.0041, 0.0007)
0.0010 (-0.0031, 0.0051)
0.0025 (-0.0017, 0.0067)
0.0146 (0.0092, 0.0199)
0.0531 (0.0428, 0.0633)
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𝜷𝑫𝑯
ATRIAL FIBRILLATION (N=32,026)

MI

Stroke

HF

Death

Parameter
𝝁𝑴
Intercept
Atrial fibrillation
Amlodipine
Lisinopril
Atrial fibrillation x Amlodipine
Atrial fibrillation x Lisinopril
𝜷𝑴𝑴
𝜷𝑴𝑺
𝜷𝑴𝑯
𝝁𝑺
Intercept
Atrial fibrillation
Amlodipine
Lisinopril
Atrial fibrillation x Amlodipine
Atrial fibrillation x Lisinopril
𝜷𝑺𝑴
𝜷𝑺𝑺
𝜷𝑺𝑯
𝝁𝑯
Intercept
Atrial fibrillation
Amlodipine
Lisinopril
Atrial fibrillation x Amlodipine
Atrial fibrillation x Lisinopril
𝜷𝑯𝑴
𝜷𝑯𝑺
𝜷𝑯𝑯
𝝁𝑫
Intercept
Atrial fibrillation
Amlodipine
Lisinopril
Atrial fibrillation x Amlodipine
Atrial fibrillation x Lisinopril
𝜷𝑫𝑴
𝜷𝑫𝑺
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0.0730 (0.0634, 0.0826)
Baseline (excess) hazard/absolute risk*
Estimate (95% CI)
0.0111 (0.0103, 0.0119)
0.0011 (-0.0041, 0.0063)
-0.0005 (-0.0017, 0.0008)
-0.0009 (-0.0022, 0.0004)
0.0044 (-0.0046, 0.0134)
0.0059 (-0.0034, 0.0153)
0.0560 (0.0492, 0.0628)
0.0121 (0.0064, 0.0177)
0.0156 (0.0103, 0.0208)
0.0060 (0.0054, 0.0066)
0.0097 (0.0038, 0.0155)
-0.0005 (-0.0014, 0.0004)
0.0009 (-0.0001, 0.0019)
0.0014 (-0.0080, 0.0108)
0.0008 (-0.0089, 0.0105)
0.0039 (0.0014, 0.0065)
0.0241 (0.0178, 0.0304)
0.0040 (0.0010, 0.0071)
0.0051 (0.0046, 0.0056)
0.0265 (0.0179, 0.0350)
0.0027 (0.0017, 0.0037)
0.0009 (<0.0001ǂ, 0.0018)
0.0021 (-0.0117, 0.0160)
-0.0105 (-0.0231, 0.0020)
0.0580 (0.0510, 0.0650)
0.0132 (0.0077, 0.0187)
0.1251 (0.1135, 0.1366)
0.0263 (0.0251, 0.0275)
0.0260 (0.0153, 0.0366)
-0.0008 (-0.0028, 0.0011)
-0.0003 (-0.0023, 0.0017)
-0.0189 (-0.0337, -0.0040)⸶
-0.0186 (-0.0341, -0.0031)⸶
0.0145 (0.0091, 0.0198)
0.0524 (0.0421, 0.0627)

𝜷𝑫𝑯
0.0720 (0.0624, 0.0816)
Abbreviations: HF, heart failure; MI, myocardial infarction.
*Excess hazard/absolute risk is the additional hazard/risk imparted by a risk factor compared to
its reference group.
⸶Statistically significant interaction
ǂDue to rounding; absolute value is between 0 and 0.0001
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Table 7. Final IRHCM

MI

Stroke

Baseline (excess) hazard/absolute risk*
Estimate (95% CI)

Parameter
𝝁𝑴
Intercept
Age
65-79
≥ 80
Diabetes
Previous MI or stroke
Sex
Previous CABG
History of OASCVD
Kidney disease
Aspirin use
Smoking
Past
Current
Amlodipine
Lisinopril
𝜷𝑴𝑴
Intercept
Sex
Kidney disease
𝜷𝑴𝑺
𝜷𝑴𝑯
Intercept
Diabetes
𝝁𝑺
Intercept
Age⸶
Diabetes
Previous MI or stroke
Sex
Hypertension (Stage 2)
Atrial fibrillation
Kidney disease
Smoking (Current)
Amlodipine
Lisinopril
𝜷𝑺𝑴
𝜷𝑺𝑺
𝜷𝑺𝑯

0.0012 (0.0001, 0.0022)
0.0036 (0.0026, 0.0045)
0.0066 (0.0039, 0.0093)
0.0029 (0.0018, 0.0039)
0.0046 (0.0030, 0.0061)
0.0037 (0.0026, 0.0047)
0.0089 (0.0066, 0.0112)
0.0019 (0.0007, 0.0032)
0.0019 (0.0004, 0.0034)
0.0018 (0.0007, 0.0030)
0.0012 (0.0002, 0.0023)
0.0032 (0.0019, 0.0045)
-0.0003 (-0.0014, 0.0008)
-0.0002 (-0.0012, 0.0009)
0.0342 (0.0228, 0.0456)
0.0218 (0.0079, 0.0357)
0.0246 (0.0061, 0.0431)
0.0090 (0.0034, 0.0147)
0.0060 (<0.0001ǂ, 0.0120)
0.0136 (0.0029, 0.0242)
0.0007 (0.0001, 0.0012)
0.0023 (0.0020, 0.0026)
0.0030 (0.0022, 0.0038)
0.0041 (0.0030, 0.0052)
0.0013 (0.0007, 0.0019)
0.0014 (0.0005, 0.0023)
0.0089 (0.0049, 0.0130)
0.0013 (0.0002, 0.0024)
0.0024 (0.0014, 0.0033)
-0.0004 (-0.0010, 0.0002)
0.0007 (-0.0002, 0.0015)
0.0031 (0.0006, 0.0056)
0.0226 (0.0160, 0.0291)
0.0032 (0.0002, 0.0063)
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HF

Death

𝝁𝑯
Intercept
Age (≥ 80)
Diabetes
Previous MI or stroke
Previous CABG
Hypertension (Stage 2)
History of OASCVD
Atrial fibrillation
Kidney disease
Smoking (Current)
LVH by echocardiogram
Amlodipine
Lisinopril
𝜷𝑯𝑴
Intercept
Age
65-79
≥ 80
Diabetes
History of OASCVD
Kidney disease
Amlodipine
𝜷𝑯𝑺
𝜷𝑯𝑯
Intercept
Lisinopril
𝝁𝑫
Intercept
Age
65-79
≥ 80
Diabetes
Previous MI or stroke
Sex
Black
History of OASCVD
Atrial fibrillation
Kidney disease
Smoking
Past
Current

0.0007 (0.0002, 0.0011)
0.0062 (0.0036, 0.0088)
0.0037 (0.0029, 0.0046)
0.0043 (0.0031, 0.0054)
0.0039 (0.0023, 0.0055)
0.0016 (0.0008, 0.0025)
0.0015 (0.0006, 0.0024)
0.0228 (0.0172, 0.0284)
0.0036 (0.0023, 0.0049)
0.0008 (0.0001, 0.0016)
0.0023 (0.0005, 0.0040)
0.0020 (0.0011, 0.0028)
0.0005 (-0.0002, 0.0012)
0.0124 (0.0033, 0.0216)
0.0182 (0.0056, 0.0308)
0.0627 (0.0232, 0.1022)
0.0431 (0.0280, 0.0582)
0.0183 (0.0023, 0.0342)
0.0275 (0.0081, 0.0470)
0.0160 (0.0005, 0.0314)
0.0114 (0.0058, 0.0171)
0.1278 (0.1135, 0.1422)
-0.0302 (-0.0553, -0.0051)
0.0009 (-0.0001, 0.0018)
0.0104 (0.0089, 0.0120)
0.0551 (0.0491, 0.0612)
0.0088 (0.0072, 0.0104)
0.0089 (0.0068, 0.0110)
0.0061 (0.0046, 0.0076)
0.0029 (0.0015, 0.0043)
0.0027 (0.0011, 0.0043)
0.0093 (0.0034, 0.0151)
0.0146 (0.0119, 0.0172)
0.0033 (0.0019, 0.0047)
0.0143 (0.0122, 0.0164)
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Amlodipine
0.0003 (-0.0009, 0.0015)
Lisinopril
-0.0002 (-0.0014, 0.0010)
𝜷𝑫𝑴
Intercept
-0.0013 (-0.0069, 0.0042)
Age ≥ 65
0.0176 (0.0085, 0.0268)
𝜷𝑫𝑺
Intercept
0.0228 (0.0114, 0.0342)
0.0228 (0.0166, 0.0290)
Age⸶
𝜷𝑫𝑯
Intercept
0.0524 (0.0365, 0.0684)
Age ≥ 65
0.0203 (0.0002, 0.0403)
*Excess hazard/absolute risk is the additional hazard/risk imparted by a risk factor compared to
its reference group.
⸶Age as an ordinal variable (see Table 1 for details) was found to yield an improved goodness of
fit (reflected by higher AUC’s) as compared to Age ≥ 80, so ordinal Age was retained for the final
IRHCM.
ǂDue to rounding; absolute value is between 0 and 0.0001
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Table 8. Area under the curve for the IRHCM.
Year
1
2
3
4

0 events
N=30,295
0.67
(0.65, 0.68)
0.67
(0.66, 0.68)
0.68
(0.67, 0.69)
0.68
(0.68, 0.69)

1+ events
N=3,358
0.62
(0.60, 0.64)
0.64
(0.62, 0.66)
0.64
(0.62, 0.66)
0.66
(0.64, 0.68)

2+ events
N=940
0.59
(0.55, 0.62)
0.60
(0.57, 0.64)
0.62
(0.58, 0.66)
0.66
(0.61, 0.70)
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3+ events
N=370
0.59
(0.53, 0.65)
0.64
(0.57, 0.70)
0.65
(0.57, 0.73)
0.64
(0.53, 0.75)

4+ events
N=145
0.63
(0.54, 0.72)
0.65
(0.54, 0.76)
0.73
(0.60, 0.85)
0.80
(0.67, 0.94)

CHAPTER 4: JOURNAL ARTICLE 3
A Supervised Learning Approach to a Competing Risk Model for Multi-type Recurrent Events
ABSTRACT
We adopt a supervised learning approach, utilizing bagged training sets and test sets to stabilize
and validate our models described previously (IHCM 1 and IRHCM) to quantify multi-type
recurrent events hazards in a competing risk framework, with death as the dependent
terminating event. A total of 250 bagged training sets at 70% and 60% yielded similar tuned
parameter estimates for IHCM 1, with smaller standard errors for 70% bagging, which showed
lisinopril to impart a statistically significant intrinsic hazard of stroke and HF compared to
chlorthalidone. Bagging at 70% and 60% showed similar performance in predictive capabilities
on the full ALLHAT dataset and on corresponding test sets (30% and 40%, respectively). IRHCM
bagged training sets at 70% yielded tuned parameter estimates with smaller standard errors
compared to previous IRHCM results and similar results for lisinopril as bagged IHCM 1 (70%).
IRHCM also performed similarly on the full dataset and relatively well on its corresponding test
sets (30%). Bagging in a supervised learning framework accomplished our aims of stabilizing and
validating our models in conjunction with variable selection.
INTRODUCTION
In our previous work, we first proposed a dynamic competing risk model for multi-type
recurrent events and applied the model in the important setting of cardiovascular disease (CVD)
to the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
study.1 We subsequently extended the model to incorporate CVD risk factors as covariates for
multiple cardiovascular (CV) outcomes in a competing risk framework for both incident and
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recurrent CVD events [myocardial infarction (MI), stroke, heart failure (HF) and death from any
cause (death)] with significant potential to develop a CV risk assessment/risk score tailored to
the individual’s clinical profile, that would be widely utilized by physicians for therapeutic
management.2 In this paper, we will implement a supervised learning approach to further
develop our model in the following ways: 1) tune the estimated parameters for the models
described in our second paper, IHCM 1 and IRHCM 2; 2) utilize the tuned parameters and their
newly constructed 95% confidence intervals (CI) for potential variable selection; and 3) validate
the model with the use of training sets and test sets.
METHODS
Parameter tuning and construction of confidence interval
All of our statistical analyses were carried out in R 3.4.4 (R Foundation for Statistical
Computing, Vienna, Austria). For IHCM 1, we first split the full ALLHAT dataset (𝑛 = 30,295)
described in detail in our second paper 2 into 4 subsets: individuals that had 0 events throughout
the in-trial portion of ALLHAT (𝑛 = 26,937); individuals who had 1 event (𝑛 = 2,418);
individuals who had 2 events (𝑛 = 570); and individuals who had 3 or more events (𝑛 = 370).
We then created 250 bagged training sets by randomly selecting 70% of observations from each
of the 4 subsets, i.e. we randomly selected 70% of observations (𝑛 = 18,856) from individuals
who had 0 events, 70% of observations (𝑛 = 1,693) from individuals who had 1 event, 70% of
observations (𝑛 = 399) from individuals who had 2 events, and 70% of observations (𝑛 = 259)
from individuals who had 3+ events, and combining all of these observations into a single bagged
training set (𝑛 = 21,207). This was done to ensure that each bagged training set was balanced

90

with respect to preserving the relative proportions of CVD events of the original ALLHAT dataset.
This procedure was repeated for a total of 250 bagged training sets.
We fitted IHCM 1 for each bagged training set to obtain the parameter estimates via the
modified Newton Raphson optimization algorithm described in our first paper.1 We obtained the
final parameter estimates for IHCM 1 by taking the mean of the 250 bagged parameter estimates,
and the standard error of each final parameter estimate by taking the standard deviation of the
250 bagged parameter estimates for each parameter. We then constructed the 95% Wald CI for
each parameter using the final parameter estimate and its standard error.
We then applied the IHCM 1 parameter estimates, tuned by the 250 bagged training sets,
to the original ALLHAT dataset (𝑛 = 30,295) to assess the goodness of fit for IHCM 1 using the
approach that we described in our previous papers.1,2 Very briefly, we predicted event-free
survival at 1-year, 2-year, 3-year and 4-year increments for all individuals at baseline, individuals
that had 1 or more events, individuals that had 2 or more events, individuals that had 3 or more
events and individuals that had 4 or more events. The ALLHAT dataset contained the binary result
of whether or not that individual had any event, nonfatal or fatal, within that time frame;
censored observations were handled in a manner identical to that detailed in our previous
work.1,2 The estimated area under the curve (AUC) and its standard error of the resulting receiver
operating characteristic (ROC) curve for each time frame and number of events were obtained
and this AUC was a measure of goodness of fit for the model.
We repeated the above procedures for ICHM 1 with 250 bagged training sets of 60%, i.e.
each training set contained randomly selected 60% of observations from each of the 4 subsets
[60% of observations (𝑛 = 16,162) from individuals who had 0 events, 60% of observations (𝑛 =
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1,451) from individuals who had 1 event, 60% of observations (𝑛 = 342) from individuals who
had 2 events, and 60% of observations (𝑛 = 222) from individuals who had 3+ events, and
combining all of these observations into a single bagged training set (𝑛 = 18,177)]. The final
parameter estimates and their 95% CI’s were constructed in the same manner and the goodness
of fit assessed.
We repeated the entire procedure for the IRHCM described in our second paper

2

to

obtain 200 bagged training sets, the final IRHCM parameter estimates and their 95% CI’s and
goodness of fit. IRHCM has more parameters (77) than IHCM 1 (64) and takes longer to converge;
due to constraints of computing speed and resources, we opted for 200 bagged training sets for
IRHCM.
Supervised learning and model validation
For IHCM 1, each bagged training set (70% and 60%, respectively) had a corresponding
test set (30% and 40%, respectively). The IHCM 1 parameters estimated from each bagged
training set were applied to its corresponding test set (which was data that the model had never
seen before, having been trained on the training set only). The resulting goodness of fit for the
test set was obtained in the same manner described in the preceding section, with a slight
adjustment: due to the small size of the test set (30%, 𝑛 = 9,088; and 40%, 𝑛 = 12,118), we
predicted event-free survival at 1-year, 2-year and 3-year increments for all individuals at
baseline (30%, 𝑛 = 9,088; and 40%, 𝑛 = 12,118), individuals that had 1 or more events (30%,
𝑛 = 1,007; and 40%, 𝑛 = 1,343), individuals that had 2 or more events (30%, 𝑛 = 282; and 40%,
𝑛 = 376) and individuals that had 3 or more events (30%, 𝑛 = 111; and 40%, 𝑛 = 148). The
resulting goodness of fit AUC’s for the 250 bagged test sets (30% and 40%, respectively) were
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averaged, and the resulting mean goodness of fit AUC was the final estimate. The standard errors
of each AUC final estimate were obtained by taking the standard deviation of the corresponding
250 bagged goodness of fit AUC’s, and subsequently used to construct the 95% Wald CI for each
AUC estimate.
The above procedure was repeated for the IRHCM for the 200 bagged training sets (70%)
and their corresponding test sets (30%) and the final goodness of fit AUC’s and their standard
errors calculated, with resulting 95% Wald CI for each AUC.
RESULTS
The tuned parameters and their 95% CI’s of IHCM 1 for both the 70% and 60% bagged
training sets are reported in Table 1. The tuned parameter estimates for the 70% and 60% bagged
training sets are very close or identical to one another. The corresponding standard errors for the
60% bagged sets are larger for every parameter estimate than that of the 70% bagged sets; as a
result, the corresponding 95% CI for each parameter is wider for the 60% bagged sets than the
70% bagged sets. The lisinopril treatment arm compared to chlorthalidone imparts a statistically
significant intrinsic hazard for stroke [0.0007 (<0.00011, 0.0013)] and HF [0.0005 (<0.00011,
0.0009)], respectively for the 70% bagged sets; in contrast, lisinopril does not impart a statistically
significant hazard compared to chlorthalidone for stroke and HF in the 60% bagged sets. Both the
tuned parameters of the 70% (Table 2a) and the 60% bagged sets (Table 2b) yield essentially
identical AUC’s as goodness of fit measures when applied to the original ALLHAT dataset
(𝑛 = 30,295). The 70% bagged training set parameters’ performance on their corresponding

Due to rounding; lower 95% CI limit is between 0 and 0.0001
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30% test sets (Table 3a) is nearly identical to that of the 60% bagged training set parameters’
performance on their 40% test sets (Table 3b), with the 70% performing slightly better for
individuals with 2+ events at the 1-year mark, and for individuals with 3+ events at the 3-year
mark. Both the 70% and the 60% bagged training set parameters essentially retain their
predictive abilities for individuals at baseline (0 events), with a decrease in prediction for
individuals with 1+ events, further decrease in prediction for individuals with 2+ events, and then
increase in prediction for individuals with 3+ events, which continues to improve from the 1-year
mark to the 3-year mark, at which point it essentially catches up to the 3-year mark for all
individuals (0 events).
The tuned parameters and their 95% CI’s of IRHCM for the 200 bagged training sets (70%)
are reported in Table 4. Similar to the bagged IHCM 1, the lisinopril treatment arm compared to
chlorthalidone imparts a statistically significant intrinsic hazard for stroke [0.0007 (<0.0001 1,
0.0013)] and HF [0.0005 (0.0001, 0.0010)], respectively. In contrast, the IRHCM from our previous
paper 2 did not show lisinopril (compared to chlorthalidone) as a statistically significant covariate
for intrinsic hazard of stroke, nor HF. The tuned parameters of IRHCM yielded by the bagged
training sets is overall very similar or identical to IRHCM of our previous paper, 2 with smaller
standard errors reflected in narrower 95% CI’s for the bagged IRHCM parameters. Moreover, the
tuned IRHCM parameters of the 70% bagged sets (Table 5) yield identical AUC’s as goodness of
fit measures when applied to the original ALLHAT dataset (𝑛 = 30,295), as the original IRHCM
parameters reported previously.2 The IRHCM 70% bagged training set parameters’ performance
on their corresponding 30% test sets is reported in Table 6. IRHCM performs comparatively to
IHCM 1’s 70% bagged training set parameters for individuals at baseline (0 events); IRHCM
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slightly outperforms IHCM 1 for individuals with 1+ and 2+ events, and slightly decreases in
predictive performance for individuals with 3+ events compared to IHCM 1.
DISCUSSION
In this paper, we wished to further develop our model in several important ways: first, we
wanted to improve our parameter estimates for our previously described models (IHCM 1 and
IRHCM) with the potential for variable selection. We also wanted to stabilize the models by
reducing the standard errors of the parameter estimates and finally, we wished to validate our
models by assessing its predictive capabilities on data it has never seen.
To accomplish all of these aims, we elected a supervised learning approach by training
our models on a subset of the full ALLHAT dataset (𝑛 = 30,295) utilized in our second paper 2
and then running the trained models on the remaining subset. Supervised learning is a wellestablished type of machine learning algorithm that can address and improve common problems
of statistical models including overfitting.3 Specifically, bagging (also known as bootstrap
aggregating) is a machine learning algorithm designed to improve the stability and accuracy of
models and reduces variance and overfitting.4 It is easily incorporated into a supervised learning
approach in the manner described here.
Our bagged training sets (70%) yielded stable parameter estimates for IHCM and IRHCM
with reduced standard errors which resulted in tighter 95% CI’s for each parameter estimate.
This directly resulted in a type of variable selection, in that the lisinopril treatment arm (in
comparison to chlorthalidone) was found to impart a statistically significant intrinsic hazard for
stroke and HF. A statistically significant higher risk of stroke in the lisinopril arm compared to
chlorthalidone, and a statistically significant higher risk of HF in the lisinopril arm compared to
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chlorthalidone have been reported previously.5,6 Our updated IHCM 1 and IRHCM results are thus
consistent with previous ALLHAT results. Due to the tuned parameter estimates for IHCM 1 and
IRHCM in this paper being very close or identical to our previously reported IHCM 1 and IRHCM
results, they performed comparatively with respect to goodness of fit measures on the full
ALLHAT dataset.
We also validated our model by running each model trained on the bagged training set,
on its corresponding test set. Both the 70% and the 60% training set models for both IHCM 1 and
IRHCM performed comparatively with respect to their predictive capabilities on their 30% and
40% test sets, respectively. IHCM 1 and IRHCM retained their predictive abilities on the test set,
i.e. data it has never seen before, for all individuals at baseline (0 events), with similar decreases
for individuals with 1+ and 2+ events, and again increasing for individuals with 3+ events, and
improvement with later time points (3-year mark vs 1-year mark). These results suggest that our
model is robust and performs relatively well on data it has never seen, and does not suffer from
the common problem of overfitting.
We acknowledge one or two limitations that should be considered as future directions
and further extensions of our work. Due to the computing resources and length of time required
for our models to converge, particularly the IRHCM, we limited our number of bagged training
sets to 250 and 200, respectively for IHCM 1 and IRHCM. It is likely and in fact probable, that our
models would have been improved if we had performed 1,000 bagged training sets which would
have resulted in more stable estimates with smaller standard errors and tighter 95 CI’s. This may
have yielded improved goodness of fit measures on the original ALLHAT dataset, whereas our
current models performed about the same. Furthermore, the IRHCM dropped slightly in its
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predictive capabilities for individuals with 3+ events compared to IHCM 1, and this was likely
driven by IRHCM performing slightly worse in individuals with 3 events; since individuals who had
4+ events were combined with this group, IRHCM’s likely better performance in that group was
not captured. In any case, the lowered performance for both IHCM 1 and IRHCM for individuals
with 1+, 2+ and 3+ events compared to all individuals at baseline (0 events) and individuals with
4+ events has been discussed at length in our previous paper, with ways to address it in future
work.2
Overall, we accomplished our aims of stabilizing our model, with reduced standard errors
and tighter confidence intervals that resulted in a type of variable selection with important
ramifications (i.e. lisinopril imparts a statistically significant intrinsic hazard for stroke and HF,
relative to chlorthalidone). Furthermore, we validated our model by showing its ability to
perform relatively well and retain its predictive capabilities in data it has never seen, and in so
doing, we directly addressed a limitation in our previous work in which we trained the models on
the full dataset and assessed prediction on the same dataset. Bagging in a supervised learning
framework is a valuable and powerful tool to improve and stabilize existing models, as well as
validating them.
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Table 1. IHCM, tuned parameters from 250 bagged datasets

MI

Stroke

HF

Parameter
𝝁𝑴
Intercept
Age
65-79
≥ 80
Diabetes
Previous MI or stroke
Sex
Previous CABG
History of OASCVD
Kidney disease
Aspirin use
Smoking
Past
Current
Amlodipine
Lisinopril
𝜷𝑴𝑴
𝜷𝑴𝑺
𝜷𝑴𝑯
𝝁𝑺
Intercept
Age*
Diabetes
Previous MI or stroke
Sex
Hypertension (Stage 2)
Atrial fibrillation
Kidney disease
Smoking (Current)
Amlodipine
Lisinopril
𝜷𝑺𝑴
𝜷𝑺𝑺
𝜷𝑺𝑯
𝝁𝑯
Intercept
Age (≥ 80)

Baseline (excess) hazard/absolute risk*
70/30
60/40
Estimate (95% CI)
Estimate (95% CI)
0.0011 (0.0003, 0.0018)

0.0010 (0.0001, 0.0020)

0.0035 (0.0028, 0.0042)
0.0064 (0.0047, 0.0080)
0.0030 (0.0023, 0.0037)
0.0046 (0.0036, 0.0056)
0.0038 (0.0031, 0.0044)
0.0089 (0.0074, 0.0103)
0.0020 (0.0011, 0.0028)
0.0019 (0.0009, 0.0029)
0.0018 (0.0010, 0.0026)

0.0035 (0.0026, 0.0044)
0.0064 (0.0042, 0.0085)
0.0031 (0.0022, 0.0039)
0.0046 (0.0034, 0.0058)
0.0038 (0.0030, 0.0046)
0.0089 (0.0072, 0.0106)
0.0020 (0.0009, 0.0031)
0.0019 (0.0007, 0.0032)
0.0018 (0.0008, 0.0028)

0.0013 (0.0005, 0.0020)
0.0033 (0.0024, 0.0042)
-0.0003 (-0.0011, 0.0004)
-0.0001 (-0.0009, 0.0006)
0.0541 (0.0499, 0.0582)
0.0091 (0.0053, 0.0129)
0.0123 (0.0090, 0.0155)

0.0013 (0.0004, 0.0022)
0.0033 (0.0022, 0.0044)
-0.0003 (-0.0013, 0.0006)
-0.0001 (-0.0011, 0.0008)
0.0540 (0.0492, 0.0589)
0.0092 (0.0043, 0.0141)
0.0122 (0.0081, 0.0163)

0.0006 (0.0002, 0.0011)
0.0023 (0.0019, 0.0027)
0.0030 (0.0025, 0.0036)
0.0041 (0.0033, 0.0049)
0.0013 (0.0008, 0.0019)
0.0014 (0.0008, 0.0020)
0.0090 (0.0061, 0.0118)
0.0013 (0.0005, 0.0021)
0.0024 (0.0018, 0.0030)
-0.0005 (-0.0012, 0.0002)
0.0007 (<0.0001ǂ, 0.0013)⸶
0.0032 (0.0014, 0.0049)
0.0227 (0.0186, 0.0267)
0.0032 (0.0012, 0.0052)

0.0006 (<0.0001, 0.0013)
0.0023 (0.0018, 0.0028)
0.0031 (0.0023, 0.0038)
0.0041 (0.0032, 0.0050)
0.0014 (0.0007, 0.0021)
0.0014 (0.0006, 0.0022)
0.0090 (0.0056, 0.0125)
0.0013 (0.0004, 0.0023)
0.0024 (0.0016, 0.0032)
-0.0005 (-0.0014, 0.0003)
0.0007 (-0.0001, 0.0014)
0.0032 (0.0008, 0.0055)
0.0227 (0.0177, 0.0277)
0.0033 (0.0007, 0.0059)

0.0006 (0.0004, 0.0009)
0.0065 (0.0046, 0.0084)

0.0006 (0.0003, 0.0010)
0.0065 (0.0041, 0.0088)
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Diabetes
0.0038 (0.0033, 0.0044)
0.0039 (0.0032, 0.0045)
Previous MI or stroke
0.0042 (0.0033, 0.0050)
0.0041 (0.0032, 0.0051)
Previous CABG
0.0039 (0.0028, 0.0050)
0.0039 (0.0025, 0.0053)
Hypertension (Stage 2)
0.0016 (0.0010, 0.0022)
0.0016 (0.0009, 0.0024)
History of OASCVD
0.0016 (0.0010, 0.0022)
0.0016 (0.0008, 0.0023)
Atrial fibrillation
0.0229 (0.0194, 0.0264)
0.0229 (0.0187, 0.0271)
Kidney disease
0.0037 (0.0028, 0.0046)
0.0037 (0.0025, 0.0048)
Smoking (Current)
0.0008 (0.0003, 0.0013)
0.0008 (0.0002, 0.0015)
LVH by
0.0023 (0.0011, 0.0035)
0.0023 (0.0009, 0.0038)
echocardiogram
Amlodipine
0.0019 (0.0014, 0.0025)
0.0019 (0.0012, 0.0027)
ǂ
⸶
Lisinopril
0.0005 (-0.0001, 0.0011)
0.0005 (<0.0001 , 0.0009)
𝜷𝑯𝑴
0.0556 (0.0507, 0.0606)
0.0557 (0.0496, 0.0618)
𝜷𝑯𝑺
0.0115 (0.0077, 0.0153)
0.0115 (0.0071, 0.0159)
𝜷𝑯𝑯
0.1227 (0.1143, 0.1312)
0.1226 (0.1115, 0.1337)
Death
𝝁𝑫
Intercept
0.0008 (-0.0002, 0.0017)
0.0007 (-0.0005, 0.0020)
Age
65-79
0.0109 (0.0099, 0.0120)
0.0109 (0.0097, 0.0122)
≥ 80
0.0563 (0.0525, 0.0601)
0.0563 (0.0515, 0.0611)
Diabetes
0.0085 (0.0074, 0.0095)
0.0085 (0.0071, 0.0098)
Previous MI or stroke
0.0088 (0.0076, 0.0101)
0.0088 (0.0071, 0.0105)
Sex
0.0060 (0.0049, 0.0070)
0.0060 (0.0046, 0.0073)
Black
0.0030 (0.0021, 0.0039)
0.0030 (0.0019, 0.0042)
History of OASCVD
00028 (0.0017, 0.0038)
00028 (0.0014, 0.0042)
Atrial fibrillation
0.0097 (0.0061, 0.0133)
0.0097 (0.0051, 0.0144)
Kidney disease
0.0146 (0.0129, 0.0163)
0.0146 (0.0123, 0.0169)
Smoking
Past
0.0033 (0.0023, 0.0044)
0.0034 (0.0021, 0.0047)
Current
0.0142 (0.0128, 0.0156)
0.0143 (0.0125, 0.0160)
Amlodipine
0.0003 (-0.0008, 0.0014)
0.0003 (-0.0011, 0.0017)
Lisinopril
-0.0004 (-0.0016, 0.0009) -0.0004 (-0.0020, 0.0011)
𝜷𝑫𝑴
0.0086 (0.0053, 0.0120)
0.0085 (0.0043, 0.0127)
𝜷𝑫𝑺
0.0418 (0.0347, 0.0488)
0.0419 (0.0336, 0.0502)
𝜷𝑫𝑯
0.0679 (0.0613, 0.0745)
0.0679 (0.0599, 0.0759)
*Excess hazard/absolute risk is the additional hazard/risk imparted by a risk factor compared to
its reference group.
⸶Statistically significant covariate from bagging
ǂDue to rounding; absolute value is between 0 and 0.0001
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Table 2a. Area under the curve for the tuned IHCM (70/30)
Year
1
2
3
4

0 events
N=30,295
0.67
(0.65, 0.68)
0.67
(0.66, 0.68)
0.68
(0.67, 0.69)
0.68
(0.68, 0.69)

1+ events
N=3,358
0.61
(0.59, 0.63)
0.63
(0.61, 0.65)
0.63
(0.61, 0.65)
0.63
(0.61, 0.65)

2+ events
N=940
0.57
(0.54, 0.61)
0.58
(0.54, 0.62)
0.59
(0.55, 0.64)
0.62
(0.57, 0.67)

3+ events
N=370
0.60
(0.54, 0.66)
0.64
(0.58, 0.70)
0.67
(0.59, 0.75)
0.65
(0.55, 0.76)

4+ events
N=145
0.67
(0.58, 0.76)
0.68
(0.57, 0.78)
0.70
(0.57, 0.82)
0.70
(0.56, 0.84)

3+ events
N=370
0.60
(0.54, 0.66)
0.64
(0.58, 0.70)
0.67
(0.59, 0.75)
0.65
(0.55, 0.76)

4+ events
N=145
0.67
(0.58, 0.76)
0.68
(0.57, 0.78)
0.70
(0.57, 0.82)
0.70
(0.56, 0.84)

Table 2b. Area under the curve for the tuned IHCM (60/40)
Year
1
2
3
4

0 events
N=30,295
0.67
(0.65, 0.68)
0.67
(0.66, 0.68)
0.68
(0.67, 0.69)
0.68
(0.68, 0.69)

1+ events
N=3,358
0.61
(0.59, 0.63)
0.63
(0.61, 0.65)
0.63
(0.61, 0.65)
0.63
(0.61, 0.65)

2+ events
N=940
0.57
(0.54, 0.61)
0.58
(0.54, 0.62)
0.59
(0.55, 0.64)
0.62
(0.57, 0.67)
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Table 3a. Area under the curve for IHCM test set (70/30)
Year
1
2
3

0 events
N=9,088
0.67
(0.65, 0.69)
0.67
(0.66, 0.69)
0.68
(0.66, 0.69)

1+ events
N=1,007
0.61
(0.58, 0.64)
0.63
(0.60, 0.65)
0.63
(0.60, 0.65)

2+ events
N=282
0.58
(0.53, 0.63)
0.58
(0.54, 0.63)
0.60
(0.55, 0.65)

3+ events
N=111
0.60
(0.50, 0.70)
0.64
(0.56, 0.72)
0.68
(0.58, 0.77)

Table 3b. Area under the curve for IHCM test set (60/40)
Year
1
2
3

0 events
N=12,118
0.67
(0.65, 0.69)
0.67
(0.66, 0.69)
0.68
(0.67, 0.69)

1+ events
N=1,343
0.61
(0.59, 0.64)
0.63
(0.61, 0.65)
0.63
(0.61, 0.64)

2+ events
N=376
0.57
(0.54, 0.61)
0.58
(0.55, 0.62)
0.60
(0.56, 0.64)
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3+ events
N=148
0.60
(0.53, 0.68)
0.64
(0.57, 0.71)
0.67
(0.60, 0.75)

Table 4. IRHCM, tuned parameters from 200 bagged datasets (70/30)
Baseline (excess) hazard/absolute risk*
Parameter
Estimate (95% CI)
MI
𝝁𝑴
Intercept
0.0011 (0.0004, 0.0018)
Age
65-79
0.0035 (0.0029, 0.0042)
≥ 80
0.0066 (0.0048, 0.0083)
Diabetes
0.0029 (0.0022, 0.0036)
Previous MI or stroke
0.0046 (0.0036, 0.0056)
Sex
0.0037 (0.0030, 0.0044)
Previous CABG
0.0089 (0.0074, 0.0103)
History of OASCVD
0.0019 (0.0011, 0.0028)
Kidney disease
0.0018 (0.0008, 0.0028)
Aspirin use
0.0018 (0.0010, 0.0027)
Smoking
Past
0.0013 (0.0005, 0.0020)
Current
0.0033 (0.0024, 0.0042)
Amlodipine
-0.0003 (-0.0011, 0.0004)
Lisinopril
-0.0002 (-0.0009, 0.0006)
𝜷𝑴𝑴
Intercept
0.0340 (0.0256, 0.0424)
Sex
0.0217 (0.0124, 0.0310)
Kidney disease
0.0242 (0.0102, 0.0382)
𝜷𝑴𝑺
0.0089 (0.0050, 0.0129)
𝜷𝑴𝑯
Intercept
0.0060 (0.0020, 0.0099)
Diabetes
0.0138 (0.0066, 0.0210)
Stroke
𝝁𝑺
Intercept
0.0006 (0.0002, 0.0011)
Age*
0.0023 (0.0019, 0.0027)
Diabetes
0.0031 (0.0025, 0.0036)
Previous MI or stroke
0.0041 (0.0033, 0.0049)
Sex
0.0013 (0.0008, 0.0018)
Hypertension (Stage 2)
0.0014 (0.0007, 0.0020)
Atrial fibrillation
0.0089 (0.0060, 0.0117)
Kidney disease
0.0013 (0.0006, 0.0021)
Smoking (Current)
0.0024 (0.0018, 0.0030)
Amlodipine
-0.0005 (-0.0012, 0.0002)
Lisinopril
0.0007 (<0.0001ǂ, 0.0013)⸶
𝜷𝑺𝑴
0.0032 (0.0014, 0.0050)
𝜷𝑺𝑺
0.0227 (0.0186, 0.0267)
𝜷𝑺𝑯
0.0032 (0.0012, 0.0052)
103

HF

Death

𝝁𝑯
Intercept
Age (≥ 80)
Diabetes
Previous MI or stroke
Previous CABG
Hypertension (Stage 2)
History of OASCVD
Atrial fibrillation
Kidney disease
Smoking (Current)
LVH by echocardiogram
Amlodipine
Lisinopril
𝜷𝑯𝑴
Intercept
Age
65-79
≥ 80
Diabetes
History of OASCVD
Kidney disease
Amlodipine
𝜷𝑯𝑺
𝜷𝑯𝑯
Intercept
Lisinopril
𝝁𝑫
Intercept
Age
65-79
≥ 80
Diabetes
Previous MI or stroke
Sex
Black
History of OASCVD
Atrial fibrillation
Kidney disease
Smoking
Past
Current

0.0007 (0.0004, 0.0009)
0.0062 (0.0044, 0.0079)
0.0037 (0.0032, 0.0043)
0.0042 (0.0034, 0.0050)
0.0040 (0.0029, 0.0050)
0.0017 (0.0011, 0.0023)
0.0015 (0.0009, 0.0022)
0.0227 (0.0192, 0.0261)
0.0036 (0.0027, 0.0045)
0.0009 (0.0003, 0.0014)
0.0023 (0.0011, 0.0035)
0.0019 (0.0013, 0.0025)
0.0005 (0.0001, 0.0010)⸶
0.0126 (0.0063, 0.0189)
0.0178 (0.0093, 0.0262)
0.0628 (0.0319, 0.0937)
0.0430 (0.0322, 0.0538)
0.0189 (0.0070, 0.0308)
0.0273 (0.0128, 0.0417)
0.0160 (0.0052, 0.0268)
0.0116 (0.0077, 0.0154)
0.1274 (0.1170, 0.1377)
-0.0300 (-0.0509, -0.0091)
0.0008 (-0.0001, 0.0017)
0.0105 (0.0094, 0.0116)
0.0551 (0.0515, 0.0586)
0.0088 (0.0077, 0.0098)
0.0089 (0.0076, 0.0102)
0.0061 (0.0050, 0.0072)
0.0030 (0.0021, 0.0039)
0.0027 (0.0017, 0.0038)
0.0093 (0.0056, 0.0129)
0.0146 (0.0128, 0.0164)
0.0034 (0.0023, 0.0044)
0.0144 (0.0130, 0.0158)
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Amlodipine
0.0003 (-0.0007, 0.0014)
Lisinopril
-0.0004 (-0.0017, 0.0009)
𝜷𝑫𝑴
Intercept
-0.0013 (-0.0049, 0.0023)
Age ≥ 65
0.0176 (0.0121, 0.0231)
𝜷𝑫𝑺
Intercept
0.0227 (0.0137, 0.0317)
Age*
0.0227 (0.0139, 0.0315)
𝜷𝑫𝑯
Intercept
0.0524 (0.0413, 0.0636)
Age ≥ 65
0.0206 (0.0071, 0.0341)
*Excess hazard/absolute risk is the additional hazard/risk imparted by a risk factor compared to
its reference group.
⸶Statistically significant covariate from bagging
ǂDue to rounding; absolute value is between 0 and 0.0001
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Table 5. Area under the curve for the tuned IRHCM (70/30)
Year
1
2
3
4

0 events
N=30,295
0.67
(0.65, 0.68)
0.67
(0.66, 0.68)
0.68
(0.67, 0.69)
0.68
(0.68, 0.69)

1+ events
N=3,358
0.62
(0.60, 0.64)
0.64
(0.62, 0.66)
0.64
(0.62, 0.66)
0.66
(0.64, 0.68)

2+ events
N=940
0.59
(0.55, 0.62)
0.60
(0.57, 0.64)
0.62
(0.58, 0.66)
0.66
(0.61, 0.70)
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3+ events
N=370
0.59
(0.53, 0.65)
0.64
(0.57, 0.70)
0.65
(0.57, 0.73)
0.64
(0.53, 0.75)

4+ events
N=145
0.63
(0.54, 0.72)
0.65
(0.54, 0.76)
0.73
(0.60, 0.85)
0.80
(0.67, 0.94)

Table 6. Area under the curve for IRHCM test set (70/30)
Year
1
2
3

0 events
N=9,088
0.67
(0.65, 0.69)
0.67
(0.66, 0.69)
0.68
(0.66, 0.69)

1+ events
N=1,007
0.62
(0.58, 0.65)
0.64
(0.61, 0.66)
0.64
(0.62, 0.66)

2+ events
N=282
0.58
(0.54, 0.63)
0.60
(0.55, 0.65)
0.62
(0.57, 0.67)
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3+ events
N=111
0.59
(0.50, 0.68)
0.63
(0.55, 0.71)
0.65
(0.54, 0.76)

CHAPTER 5: CONCLUSIONS
This dissertation proposed a dynamic risk model that handles multi-type recurrent events
with a dependent terminating event in a competing risk framework. A unique feature of the
model is that it directly provides the baseline hazard for each type of recurrent event and the
terminating event, and the additional hazard that each recurrent event confers to all other
events. This quantifies positive and negative associations and relationships between all event
types, recurrent and terminating. The baseline hazard is dynamically updated with each event
occurrence, and is affected by event history (the number and types of past events) and
covariates. In the first paper, we derived and formulated the model and then validated the model
with a simulation study. The model was applied to the model to the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT) study and a procedure developed to
assess goodness of fit of the model, therefore accomplishing aims 1 and 2 in the important arena
of CVD.
We extended the model to incorporate risk factors for intrinsic hazards of the nonfatal
CVD events MI, stroke and HF, and all-cause mortality (death) (IHCM 1) and further extended the
model to incorporate risk factors for recurrent hazards, or for hazards imparted by antecedent
nonfatal MI, stroke and/or HF (IRHCM). Heterogeneity of treatment effects on subgroups of
patients was examined (IHCM 2). Goodness of fit for IHCM 1 and IRHCM was markedly improved
for all individuals at baseline (0 events) and with 4+ events, and modestly improved for IRHCM
for individuals with 1+ and 2+ events. Therefore, we conclude that CVD risk factors and
antecedent CVD events are predictive of future CVD events and mortality, satisfying aim 3.
Incorporation of biomarkers and time-dependent covariates in conjunction with methods to
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handle missing covariates in longitudinal data would further augment the models and should be
considered as an important future direction of this research.
Finally, IHCM 1 and IRHCM were stabilized and validated with a supervised learning
approach. Bootstrap aggregated (bagged) training sets were utilized to stabilize the parameter
estimates and construct 95% confidence intervals for every parameter using the standard
deviations of the parameter’s bagged estimates. This in turn led to potential variable selection
from stabilized parameter estimates with shrinkage of standard errors resulting in tighter 95%
CI’s. Each training set’s estimated parameters was assessed for goodness of fit on its
corresponding test set. IHCM 1 and IRHCM performed comparatively on test sets, which suggests
that both models are stable and do not have the problem of overfitting, satisfying our 4 th and
final aim.
Our proposed multi-type recurrent events model has great potential to develop into a
clinical risk assessment tool or risk score for CVD that incorporates both risk factors and event
history and is tailored to the individual’s clinical profile, and provide head-to-head comparisons
between treatment and therapeutic approaches for CVD. This would be of significant import in
reducing the enormous public health and clinical burden of CVD, in the United States and
worldwide.
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